<SEC-DOCUMENT>0001193125-24-105870.txt : 20240423
<SEC-HEADER>0001193125-24-105870.hdr.sgml : 20240423
<ACCEPTANCE-DATETIME>20240423070057
ACCESSION NUMBER:		0001193125-24-105870
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20240603
FILED AS OF DATE:		20240423
DATE AS OF CHANGE:		20240423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cabaletta Bio, Inc.
		CENTRAL INDEX KEY:			0001759138
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39103
		FILM NUMBER:		24862666

	BUSINESS ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(267) 759-3100

	MAIL ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d448465ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
INFORMATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&#8195;) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&#8194;&#9744; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of registrant as specified in its charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g448465g01a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2929 Arch Street, Suite 600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Philadelphia, PA 19104 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To be held June&nbsp;3, 2024 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice is
hereby given that the 2024 Annual Meeting of Stockholders, or Annual Meeting, of Cabaletta Bio, Inc., will be held online on June&nbsp;3, 2024 at 9:00 a.m. Eastern Time. This year&#146;s Annual Meeting will be a virtual meeting, which will be
conducted via live webcast. You may attend the meeting virtually via the Internet by registering at www.proxydocs.com/CABA, where you will be able to vote electronically and submit questions. You will need the control number included with the Notice
of Internet Availability of Proxy Materials being mailed to you separately in order to attend the Annual Meeting. The purpose of the Annual Meeting is the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect two class II directors to our board of directors, to serve until the 2027 annual meeting of
stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the appointment of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm
for the fiscal year ending December&nbsp;31, 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of
the Annual Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proposal for the election of directors relates solely to the election of two class II directors nominated by
the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only Cabaletta Bio, Inc. stockholders of record at the close of business on April&nbsp;4, 2024, will be entitled to vote at the
Annual Meeting and any adjournment or postponement thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc. is following the Securities and Exchange Commission&#146;s &#147;Notice
and Access&#148; rule that allows companies to furnish their proxy materials by posting them on the Internet. As a result, we are mailing to our stockholders a Notice of Internet Availability of Proxy Materials, or the Notice, instead of a paper
copy of the accompanying proxy statement and our Annual Report for the fiscal year ended December&nbsp;31, 2023, or 2023 Annual Report. We plan to mail the Notice on or about April&nbsp;23, 2024, and it contains instructions on how to access both
the 2023 Annual Report and accompanying proxy statement over the Internet. This method provides our stockholders with expedited access to proxy materials and not only lowers the cost of printing and distribution but also reduces the environmental
impact of the Annual Meeting. If you would like to receive a print version of the proxy materials, free of charge, please follow the instructions on the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be admitted to the Annual Meeting and vote your shares, you must register in advance at www.proxydocs.com/CABA prior to the meeting and provide the control
number as provided described in the Notice, or proxy card, or voting instruction form at www.proxydocs.com/CABA. Upon completing your registration, you will receive further instructions via email, including unique links to access the Annual Meeting
and to submit questions in advance of the Annual Meeting. Please see the &#147;General Information&#148; section of the proxy statement that accompanies this notice for more details regarding the logistics of the virtual Annual Meeting, including
the ability of stockholders to submit questions during the Annual Meeting, and technical details and support related to accessing the virtual platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your vote is important. Whether or not you expect to attend the virtual meeting, it is important that your shares be represented. To ensure that your vote is
recorded promptly, please vote as soon as possible, even if you plan to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attend the meeting, by submitting your proxy via the Internet at the address listed on the proxy card or by signing, dating and returning the proxy card. Even if you have voted by proxy, you may
still vote at the virtual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note, however, that if your shares are held through a broker, bank or other nominee and you wish to vote at the
meeting, you must obtain a proxy issued in your name from that record holder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By order of the Board of Directors,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Steven Nichtberger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>President and
Chief Executive Officer</I></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philadelphia, Pennsylvania </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;23, 2024 </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_1">OVERVIEW OF PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_2">PROPOSAL NO. 1 &#150; ELECTION OF CLASS II DIRECTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_3">PROPOSAL NO. 2 &#150; RATIFICATION OF THE APPOINTMENT OF ERNST&nbsp;
&amp; YOUNG AS CABALETTA&#146;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER&nbsp;31, 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_4">CORPORATE GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_5">EXECUTIVE OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_6">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_7">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_8">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_9">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_10">REPORT OF THE AUDIT COMMITTEE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_11">DELINQUENT SECTION 16(a) REPORTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_12">HOUSEHOLDING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_13">STOCKHOLDER PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc448465_14">OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g448465g01a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2929 Arch Street, Suite 600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Philadelphia, PA 19104 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE
2024 ANNUAL MEETING OF STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD JUNE&nbsp;3, 2024 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement contains information about the 2024 Annual Meeting of Stockholders, or the Annual Meeting, of Cabaletta Bio, Inc., which will be held
online on June&nbsp;3, 2024 at 9:00 a.m. Eastern Time. You may attend the Annual Meeting virtually via the Internet at www.proxydocs.com/CABA, where you will be able to vote electronically and submit questions. The board of directors of Cabaletta
Bio, Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms &#147;Cabaletta,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Cabaletta Bio,
Inc. The mailing address of our principal executive offices is Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All properly
submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our board of directors with respect to each of the
matters set forth in this proxy statement and the accompanying proxy card. You may revoke your proxy at any time before it is exercised at the meeting by giving our corporate secretary written notice to that effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are mailing to our stockholders a Notice of Internet Availability of proxy materials and our 2023 Annual Report on or about April&nbsp;23, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; under applicable federal securities laws and therefore permitted to conform with certain reduced public company
reporting requirements. As an emerging growth company, we provide in this proxy statement the scaled disclosure permitted under the Jumpstart Our Business Startups Act of 2012, the JOBS Act, including the compensation disclosures required of a
&#147;smaller reporting company,&#148; as that term is defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the Securities Exchange Act of 1934, as amended, the Exchange Act. In addition, as an emerging growth company, we
are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an &#147;emerging growth company&#148; until the
earliest of (i)&nbsp;the last day of the fiscal year following the fifth anniversary of our initial public offering in October 2019; (ii) the last day of the fiscal year in which our total annual gross revenue is equal to or more than
$1.235&nbsp;billion; (iii)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the
Securities and Exchange Commission, or the SEC. Even after we are no longer an &#147;emerging growth company,&#148; we may remain a &#147;smaller reporting company.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>the Annual Meeting of Stockholders to be Held on June&nbsp;3, 2024: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>This proxy statement and our 2023 Annual Report to Stockholders are </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>available for viewing, printing and downloading at </B><B><I>www.proxydocs.com/CABA</I></B><B>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A copy of our 2023 Annual Report, as filed with the SEC, except for exhibits, will be furnished without charge to any stockholder upon written request to
Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104, Attention: Corporate Secretary. This proxy statement and our 2023 Annual Report are also available on the SEC&#146;s website at</B><B><I> www.sec.gov</I></B><B>. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE
2024 ANNUAL MEETING OF STOCKHOLDERS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why are you holding a virtual Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
year&#146;s Annual Meeting will be a &#147;virtual meeting&#148; of stockholders. We have implemented the virtual format in order to facilitate stockholder attendance at our Annual Meeting. We have designed our virtual format to enhance, rather than
constrain, stockholder access, participation and communication. For example, the virtual format allows stockholders to communicate with us in advance of, and during, the Annual Meeting so they can ask questions of our board of directors or
management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I virtually attend the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To attend and participate in the Annual Meeting, stockholders will need to access the live webcast of the meeting. To do so, stockholders of record will need
to visit www.proxydocs.com/CABA and enter the control number provided in the Notice of Internet Availability of Proxy Materials, or the Notice, to preregister for the Annual Meeting prior to the deadline of June&nbsp;3, 2024 at 9:00 a.m. Eastern
Time, and beneficial owners of shares held in street name will need to follow the instructions provided in the voting instructions form by the broker, bank or other nominee that holds their shares. Upon completing the registration, stockholders will
receive further instructions via email, including a unique link to access the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The live webcast of the Annual Meeting will begin promptly
at 9:00 a.m. Eastern Time on June&nbsp;3, 2024. We encourage stockholders to login to this website and access the webcast before the Annual Meeting&#146;s start time by following the instructions in the email received on the morning of the Annual
Meeting. You should allow ample time in advance of the meeting. Additionally, questions regarding how to attend and participate via the Internet can be answered by following the assistance instructions included at www.proxydocs.com/CABA or by
calling the phone number provided in the email received on the morning of the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you wish to submit a question during the Annual Meeting,
you may log into, and submit a question on, the virtual meeting platform using the unique link provided to you via email following the completion of your registration at www.proxydocs.com/CABA and following the instructions there. Our Annual Meeting
will be governed by the Annual Meeting&#146;s Rules of Conduct and Procedures, which will address the ability of stockholders to ask questions during the meeting and rules for how questions will be recognized and addressed. The Annual Meeting&#146;s
Rules of Conduct and Procedures will be available on www.proxydocs.com/CABA prior to the Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I get help if I have trouble checking
in or listening to the meeting online? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you encounter any difficulties accessing the virtual meeting during the
<FONT STYLE="white-space:nowrap">check-in</FONT> or meeting time, please refer to the email received the morning of the Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When are this
proxy statement and the accompanying materials scheduled to be sent to stockholders? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are mailing to our stockholders a Notice instead of a paper
copy of the accompanying proxy statement and our 2023 Annual Report on or about April&nbsp;23, 2024, and it contains instructions on how to access those documents over the Internet. You will need the control number included on the Notice, proxy card
or voting instruction form to access these materials. If you would like to receive a print version of the Proxy Materials, free of charge, please follow the instructions on the Notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is soliciting my vote? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors, or
the board of directors, is soliciting your vote for the Annual Meeting, including at any adjournments or postponements of the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When is the record date for the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The record date for determination of stockholders entitled to vote at the Annual Meeting is the close of business on April&nbsp;4, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes can be cast by all stockholders? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There
were 46,804,820 shares of our voting common stock, par value $0.00001 per share, outstanding on April&nbsp;4, 2024, all of which are entitled to vote with respect to all matters to be acted upon at the Annual Meeting. Each stockholder of record is
entitled to one vote for each share of our common stock held by such stockholder. As the stockholder of record, you have the right to grant your voting proxy directly to the individuals listed on the proxy card or vote on your own behalf at our
virtual Annual Meeting. None of our shares of preferred stock were outstanding as of April&nbsp;4, 2024. As of April&nbsp;4, 2024, there were 1,444,295 shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, par value $0.00001 per
share, outstanding. The shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> stock are not entitled to vote on the proposals presented at the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is entitled to vote? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registered Stockholders</I>.
If shares of our common stock are registered directly in your name with our transfer agent, you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have the right to grant your voting proxy
directly to the individuals listed on the proxy card or vote on your own behalf at our virtual Annual Meeting. Throughout this proxy statement, we refer to these registered stockholders as &#147;stockholders of record.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Street Name Stockholders</I>. If shares of our common stock are held on your behalf in a brokerage account or by a bank or other nominee, you are
considered to be the beneficial owner of shares that are held in &#147;street name,&#148; and the proxy materials were forwarded to you by your broker or nominee, who is considered the stockholder of record with respect to those shares. As the
beneficial owner, you have the right to direct your broker, bank or other nominee as to how to vote your shares. Beneficial owners are also invited to attend our virtual Annual Meeting. However, since a beneficial owner is not the stockholder of
record, you may not vote your shares of our common stock on your own behalf at the Annual Meeting unless you follow your broker&#146;s procedures for obtaining a legal proxy. Note you should also be receiving a voting instruction form for you to use
from your broker. Throughout this proxy statement, we refer to stockholders who hold their shares through a broker, bank or other nominee as &#147;street name stockholders.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I vote? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, there
are four ways to vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>By Internet. </I></B>You may vote at <I>www.proxypush.com/CABA</I>, 24 hours a day, seven days a week. You
will need the control number included on your Notice or proxy card. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>During the Annual Meeting. </I></B>You may vote in person virtually by attending the meeting through
<I>www.proxydocs.com/CABA</I>. To attend the Annual Meeting and vote your shares, you must register for the Annual Meeting and provide the control number located on your Notice or proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>By Telephone. </I></B>You may vote using a touch-tone telephone by calling
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-430-8263,</FONT></FONT></FONT> 24 hours a day, seven days a week. You will need the control number included on your Notice or proxy card.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>By Mail</I></B>. You may vote by completing and mailing your proxy card. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if you plan to participate in our virtual Annual Meeting, we recommend that you also vote by proxy so that your vote will be counted if you later decide
not to participate in the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a street name stockholder, you will receive voting instructions from your broker, bank or other
nominee. You must follow the voting instructions provided by your broker, bank or other nominee in order to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
instruct your broker, bank or other nominee on how to vote your shares. Street name stockholders should generally be able to vote by returning an instruction card, or by telephone or on the
Internet. However, the availability of telephone and Internet voting will depend on the voting process of your broker, bank or other nominee. As discussed above, if you are a street name stockholder, you may not vote your shares on your own behalf
at the Annual Meeting unless you obtain a legal proxy from your broker, bank or other nominee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>By Proxy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you will not be attending the Annual Meeting, you may vote by proxy. You can vote by proxy over the Internet by following the instructions provided in the
enclosed proxy card. Proxies submitted by mail must be received before the start of the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you complete and submit your proxy before the
Annual Meeting, the persons named as proxies will vote the shares represented by your proxy in accordance with your instructions. If you submit a proxy without giving voting instructions, your shares will be voted in the manner recommended by the
board of directors on all matters presented in this proxy statement, and as the persons named as proxies may determine in their discretion with respect to any other matters properly presented at the Annual Meeting. You may also authorize another
person or persons to act for you as proxy in a writing, signed by you or your authorized representative, specifying the details of those proxies&#146; authority. The original writing must be given to each of the named proxies, although it may be
sent to them by electronic transmission if, from that transmission, it can be determined that the transmission was authorized by you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any other
matters are properly presented for consideration at the Annual Meeting, including, among other things, consideration of a motion to adjourn the Annual Meeting to another time or place (including, without limitation, for the purpose of soliciting
additional proxies), the persons named in your proxy and acting thereunder will have discretion to vote on those matters in accordance with their best judgment. We do not currently anticipate that any other matters will be raised at the Annual
Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I revoke my proxy? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may revoke
your proxy by (1)&nbsp;entering a new vote by mail that we receive before the start of the Annual Meeting or over the Internet or via telephone, (2)&nbsp;attending and voting at the Annual Meeting online (although attendance at the Annual Meeting
will not in and of itself revoke a proxy), or (3)&nbsp;by filing an instrument in writing revoking the proxy or another duly executed proxy bearing a later date with our Corporate Secretary. Any written notice of revocation or subsequent proxy card
must be received by our Corporate Secretary prior to the taking of the vote at the Annual Meeting. Such written notice of revocation or subsequent proxy card should be hand delivered to our Corporate Secretary or sent to our principal executive
offices at Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104, Attention: Corporate Secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a broker, bank, or other nominee
holds your shares, you must contact such broker, bank, or nominee in order to find out how to change your vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How is a quorum reached? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Bylaws, or bylaws, provide that a majority of the shares entitled to vote, present in person or represented by proxy, will constitute
a quorum for the transaction of business at the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the General Corporation Law of the State of Delaware, shares that are voted
&#147;abstain&#148; or &#147;withheld&#148; and broker <FONT STYLE="white-space:nowrap">&#147;non-votes&#148;</FONT> are counted as present for purposes of determining whether a quorum is present at the Annual Meeting. If a quorum is not present,
the meeting may be adjourned until a quorum is obtained. There were 46,804,820 shares of common stock outstanding and entitled to vote on April&nbsp;4, 2024, our record date. Therefore, a quorum will be present if 23,402,411 shares of our common
stock are present in person or represented by executed proxies timely received by us at the Annual Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How is the vote counted? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our bylaws, any proposal other than an election of directors is decided by a majority of the votes properly cast for and against such proposal, except
where a larger vote is required by law or by our Third Amended and Restated Certificate of Incorporation, or certificate of incorporation, or bylaws. Abstentions, votes withheld and broker
<FONT STYLE="white-space:nowrap">&#147;non-votes&#148;</FONT> are not included in the tabulation of the voting results on any such proposal and, therefore, do not have an impact on such proposals. A broker
<FONT STYLE="white-space:nowrap">&#147;non-vote&#148;</FONT> occurs when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have discretionary voting power with respect to that item,
and has not received instructions from the beneficial owner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in &#147;street name&#148; by a brokerage firm, your brokerage firm
is required to vote your shares according to your instructions. If you do not give instructions to your brokerage firm, the brokerage firm will still be able to vote your shares with respect to certain &#147;discretionary&#148; items, but will not
be allowed to vote your shares with respect to <FONT STYLE="white-space:nowrap">&#147;non-discretionary&#148;</FONT> items. Proposal No.&nbsp;1 is a <FONT STYLE="white-space:nowrap">&#147;non-discretionary&#148;</FONT> item. If you do not instruct
your broker how to vote your shares with respect to this proposal, your broker may not vote for this proposal, and those shares will be counted as broker <FONT STYLE="white-space:nowrap">&#147;non-votes.&#148;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be elected, a director nominated via Proposal No.&nbsp;1 must receive a plurality of the votes properly cast on the election of the director. You may vote
for the director nominees or withhold authority to vote your shares with respect to the director nominees. Shares voting &#147;withheld&#148; have no effect on the election of the directors. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT>
are not considered votes cast and will have no effect on the election of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To ratify the appointment of our independent registered public
accounting firm via Proposal No.&nbsp;2, the proposal must receive the affirmative vote of a majority of the votes properly cast &#147;For&#148; and &#147;Against&#148; the proposal. Proposal No.&nbsp;2 is considered to be a discretionary item, and
your brokerage firm will be able to vote your shares on this proposal even if it does not receive instructions from you. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> if any, will not be counted &#147;For&#148; or
&#147;Against&#148; this proposal and will have no effect on this proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who pays the cost for soliciting proxies? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are making this solicitation and will pay the entire cost of preparing and distributing our proxy materials and soliciting votes. If you choose to access
the proxy materials or vote over the Internet, you are responsible for any Internet access charges that you may incur. Our officers and employees may, without compensation other than their regular compensation, solicit proxies through further
mailings, personal conversations, facsimile transmissions, <FONT STYLE="white-space:nowrap">e-mails,</FONT> or otherwise. Proxy solicitation expenses that we will pay include those for preparation, mailing, returning, and tabulating the proxies.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How may stockholders submit matters for consideration at an Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90 days nor more than 120 days
prior to the first anniversary of the preceding year&#146;s annual meeting. However, in the event that the date of the annual meeting is advanced by more than 30 days, or delayed by more than 60 days, from the first anniversary of the preceding
year&#146;s annual meeting, or if no annual meeting were held in the preceding year, a stockholder&#146;s notice must be so received no earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of
(A)&nbsp;the 90th day prior to such annual meeting and (B)&nbsp;the tenth day following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever first occurs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, any stockholder proposal intended to be included in the proxy statement for the next annual meeting of our stockholders in 2025 must also
satisfy the requirements of SEC Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and be received not later than December&nbsp;24, 2024. In addition, to comply with the
SEC&#146;s new universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice by the same deadline noted herein to present
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
matters at the 2025 Annual Meeting of Stockholders. Such notice must comply with the additional requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(b).</FONT> If the date of the annual
meeting is moved by more than 30 days from the date contemplated at the time of the previous year&#146;s proxy statement, then notice must be received within a reasonable time before we begin to print and send proxy materials. If that happens, we
will publicly announce the deadline for submitting a proposal in a press release or in a document filed with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I find out the results
of the voting at the Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to announce preliminary voting results at the Annual Meeting. Final voting results will be published in a
Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> or Form <FONT STYLE="white-space:nowrap">8-K,</FONT> that we expect to file with the SEC within four business days after the Annual Meeting. If final voting results are not
available to us in time to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business days after the Annual Meeting, we intend to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish preliminary results and, within
four business days after the final results are known to us, file an additional Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish the final results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_1"></A>OVERVIEW OF PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement contains two proposals requiring stockholder action. Proposal No.&nbsp;1 requests the election of two Class&nbsp;II directors to our
board of directors. Proposal No.&nbsp;2 requests the ratification of the appointment of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2024. Each of the proposals is
discussed in more detail in the pages that follow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_2"></A>PROPOSAL NO. 1 &#150; ELECTION OF CLASS II DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of six members. In accordance with the terms of our certificate of incorporation and bylaws, our board of directors
is divided into three classes, class I, class II and class III, with members of each class serving staggered three-year terms. The members of the classes are divided as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the class I directors are Scott Brun, M.D. and Shawn Tomasello, and their term will expire at the annual meeting
of stockholders to be held in 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the class II directors are Catherine Bollard, MBChB, M.D., and Richard Henriques, MBA, and their terms will
expire at the Annual Meeting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the class III directors are Steven Nichtberger, M.D., and Mark Simon, MBA, and their terms will expire at the
annual meeting of stockholders to be held in 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the expiration of the term of a class of directors, directors in that class
will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate
of incorporation and bylaws provide that the authorized number of directors may be changed only by resolution of our board of directors. Our certificate of incorporation also provides that our directors may be removed only for cause by the
affirmative vote of the holders of at least seventy-five percent (75%) or more of the outstanding shares then entitled to vote in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an
enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has nominated
Catherine Bollard, MBChB, M.D., and Richard Henriques, MBA, for election as the class II directors at the Annual Meeting. The nominees are presently directors, and they have indicated a willingness to continue to serve as directors, if elected. If a
nominee becomes unable or unwilling to serve, however, the properly submitted proxies may be voted for a substitute nominee selected by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee Policies and Procedures for Director Candidates, or the Director Guidelines, provide that the value of
diversity should be considered in determining director candidates as well as other factors such as a candidate&#146;s character, judgment, skills, education, expertise and absence of conflicts of interest. Our priority in selection of board members
is identification of members who will further the interests of our stockholders through their established records of professional accomplishment, their ability to contribute positively to the collaborative culture among board members, and their
knowledge of our business and understanding of the competitive landscape in which we operate and adherence to high ethical standards. The nominating and corporate governance committee and the full board of directors are committed to creating a board
of directors with diversity, including diversity of expertise, experience, background and gender, and are committed to identifying, recruiting and advancing candidates offering such diversity in future searches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the information presented below regarding each of the nominees and continuing directors&#146; specific experience, qualifications, attributes
and skills that our board of directors and our nominating and corporate governance committee considered in determining that they should serve as a director, we also believe that each of our directors has demonstrated business acumen, integrity and
an ability to exercise sound judgment, as well as a commitment of service to Cabaletta Bio and our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominees for Election as
Class&nbsp;II Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table identifies our director nominees, and sets forth their principal occupation and business experience during
the last five years and age as of April&nbsp;4, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Positions&nbsp;and<BR>Offices Held<BR>with&nbsp;Cabaletta</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director<BR>Since</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Catherine Bollard, MBChB, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Henriques, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;II Directors (Term Expires at Annual Meeting) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Catherine Bollard, MBChB, M.D.</I></B> Dr.&nbsp;Bollard joined our board of directors in April 2019. She has been the director of the Center for Cancer
and Immunology Research at the Children&#146;s National Research Institute (CNRI) since 2017 and the director of the Program for Cell Enhancement and Technologies for Immunotherapy at the Children&#146;s National Hospital, or CNH, since 2013. She is
also a faculty member of the Division of the Blood and Marrow Transplantation at CNH. Since 2013, Dr.&nbsp;Bollard has served as a tenured Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at the George Washington University
and is the Associate Center Director (ACD) for Translational Research and Innovation within the George Washington Cancer Center. Prior to her move in 2013, Dr.&nbsp;Bollard was Professor of Pediatrics, Medicine and Immunology at Baylor College of
Medicine. She is a past president of the International Society for Cell Therapy (ISCT), and she served on the Cellular, Tissues and Gene Therapy Advisory Committee of the FDA until 2019. Dr.&nbsp;Bollard chaired the
<FONT STYLE="white-space:nowrap">Non-Hodgkin&#146;s</FONT> Lymphoma Committee of the Children&#146;s Oncology Group from 2012 to 2020 and in 2021 became the President of the Foundation for the Accreditation of Cellular Therapy (FACT).
Dr.&nbsp;Bollard was the scientific <FONT STYLE="white-space:nowrap">co-founder</FONT> of Catamaran Bio, a company developing novel, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> chimeric antigen
receptor <FONT STYLE="white-space:nowrap">(CAR)-NK</FONT> cell therapies designed to treat a broad range of cancers and served on its Scientific Advisory Board until 2024. Dr.&nbsp;Bollard was previously on the board of directors and subsequently
the Scientific Advisory Board of Mana Therapeutics. She currently serves on the SAB of Minovia Tx Ltd and serves as Chair of the DSMB for SOBI. Dr.&nbsp;Bollard received her medical degree (MBChB) and her doctor of medicine (MD)&nbsp;from the
University of Otago Medical School in New Zealand. We believe Dr.&nbsp;Bollard is qualified to serve as a member of our board of directors because of her scientific background and significant experience in clinical and translational research
efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Richard Henriques, MBA. </I></B>Mr.&nbsp;Henriques joined our board of directors in February 2019. Since 2015, he has been a senior fellow
at the Center for High Impact Philanthropy at the University of Pennsylvania, with a focus on impact investing. From 2010 to 2014, Mr.&nbsp;Henriques was the Chief Financial Officer of the Bill&nbsp;&amp; Melinda Gates Foundation, where he was
responsible for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program related investments and information technology. From 1981 to 2008, Mr.&nbsp;Henriques held positions at Merck&nbsp;&amp;
Co., Inc., including as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer. Mr.&nbsp;Henriques has served on the boards of directors of Arbutus Biopharma Corporation
(Nasdaq: ABUS) since December 2014. Mr.&nbsp;Henriques also serves on the boards of directors or trustees of the Heritage Conservancy and Episcopal Community Services, Delaware Canal 21, Fisherman&#146;s Mark and The Franklin Institute.
Mr.&nbsp;Henriques received his MBA from the Wharton School of the University of Pennsylvania and a BA from the University of Pennsylvania. We believe that Mr.&nbsp;Henriques is qualified to serve as a member of our board of directors because of his
extensive corporate leadership experience and expertise in finance and investment management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required and Board of Directors&#146;
Recommendation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in &#147;street name&#148; by a broker, bank or other nominee, your broker, bank or other nominee does not have
authority to vote your unvoted shares held by the firm for the election of the directors. As a result, any shares not voted by you will be treated as a broker <FONT STYLE="white-space:nowrap">non-vote.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be elected, the directors nominated via this Proposal must receive a plurality of the votes properly cast on the election of directors. Shares voting
&#147;withheld&#148; and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the election of directors. Shareholders do not have cumulative voting rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Properly submitted proxies will be voted in favor of the above nominees unless a contrary specification is made in the proxy. The nominees have consented to
serve as our directors if elected. However, if a nominee is unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as our board of directors may designate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The board of directors recommends voting &#147;FOR&#148; the election of Catherine Bollard, MBChB, M.D.
and Richard Henriques, MBA, as the class II directors, to serve for a three-year term ending at the annual meeting of stockholders to be held in 2027. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors Continuing in Office </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
identifies our directors, and sets forth their principal occupation and business experience during the last five years and their ages as of April&nbsp;4, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Positions and Offices Held with Cabaletta</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:9pt"><B>Director<BR>Since</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;and<BR>Year in Which<BR>Term
Will<BR>Expire</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer, President, Chairman of the Board of Directors and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;III&#151;2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Simon, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;III&#151;2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Brun, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;I&#151;2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn Tomasello, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;I&#151;2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;I Director (Term Expires at 2026 Annual Meeting) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scott Brun, M.D.</I></B> Dr.&nbsp;Brun joined our board of directors in June 2021. Dr.&nbsp;Brun is currently President at Gold Mast Consulting, LLC, an
advisory firm he founded in 2019 to provide technical advice and strategic guidance related to biopharmaceutical research and development, pipeline portfolio management, commercialization of new therapeutics and strategic communications related to
R&amp;D activities. Dr.&nbsp;Brun serves as a Venture Partner at Abingworth LLP and a Senior Medical Advisor to Launch Therapeutics. Prior to his current roles, Dr.&nbsp;Brun had two decades of experience in various leadership roles at AbbVie, Inc.,
including 15 years at the predecessor company, Abbott Laboratories. The majority of his career has been focused on leading teams and clinical development organizations across a broad variety of therapeutic areas including autoimmune, neurologic, and
renal among others. He was most recently Corporate Vice President of Scientific Affairs and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities within AbbVie&#146;s R&amp;D therapeutic areas as well as
technology platforms of interest from 2016 to 2019. Previously, Dr.&nbsp;Brun served as Corporate Vice President and Head of Pharmaceutical Development at AbbVie from 2013 to 2016. During his tenure at AbbVie, Dr.&nbsp;Brun oversaw a global
organization with responsibilities for AbbVie&#146;s entire portfolio of early and late-stage clinical <FONT STYLE="white-space:nowrap">pre-registration</FONT> pipeline compounds as well as marketed compounds within oncology, neurology, immunology,
renal, infectious disease, and women&#146;s and men&#146;s health therapeutic areas. Prior to joining AbbVie, Dr.&nbsp;Brun spent over 15 years at Abbott Laboratories, where he held positions of increasing leadership responsibility in drug
development within the R&amp;D organization. Dr.&nbsp;Brun is a member of the boards of directors of Axial Biotherapeutics, Inc. and Trishula Therapeutics, Inc., both private, clinical-stage biopharmaceutical companies, Jasper Therapeutics, Inc.
(Nasdaq: JSPR) a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases and Forte Biosciences, Inc. (Nasdaq: FBRX) a preclinical-stage company focused on autoimmune diseases. Previously, Dr.&nbsp;Brun served
as a Senior Advisor to the business development team at Horizon Therapeutics plc (Nasdaq: HZNP) from 2020 to 2023. Dr.&nbsp;Brun received his B.S. in Biochemistry from the University of Illinois at Urbana-Champaign and earned his M.D. from the Johns
Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. We believe Dr.&nbsp;Brun is qualified to serve as a member of our board of directors because of
his scientific background and significant experience in clinical and research efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shawn Tomasello, MBA</I></B><I>. </I>Ms.&nbsp;Tomasello
joined our Board of Directors in July 2023. Most recently, Ms.&nbsp;Tomasello served as the Chief Commercial Officer of Kite Pharma, where she oversaw the global commercialization of Yescarta, from 2015 to 2018 including through its acquisition by
Gilead for $11.9&nbsp;billion in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
October 2017. She was previously Chief Commercial Officer at Pharmacyclics, where she led commercial and medical affairs activities for
Imbruvica<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> treatment for hematologic malignancies, from August 2014 until its acquisition by
AbbVie for $21.0&nbsp;billion in August 2015. Prior to Pharmacyclics, Ms.&nbsp;Tomasello served in leading commercial roles with multiple major pharmaceutical companies, including Celgene as President of the Americas Hematology and Oncology, where
she led the company through five successful product launches encompassing 11 indications and played a critical role in acquisitions. At Genentech for 14 years prior, Ms.&nbsp;Tomasello was the National Director of Hematology for Rituxan. She
currently serves on the board of directors of AlloVir, Inc. (Nasdaq: ALVR) since March 2022, Gamida Cell Ltd. (Nasdaq: GMDA) since June 2019 and 4D Molecular Therapeutics Inc. (Nasdaq: FDMT) since November 2020. She previously served as a board
member of TCR2 Therapeutics Inc. (Nasdaq: TCRR) until June 2023, Urogen Pharma Ltd (Nasdaq: URGN) until 2022, Mesoblast, Ltd. (Nasdaq: MESO) until August 2022, Clementia Pharmaceuticals, Diplomat Pharmacy, Inc. until 2020, Abeona Therapeutics
(Nasdaq: ABEO) until 2020 and Principia Biopharma until 2020, as well as several private boards. On such boards, she at various times has served and serves on the Compensation, Nominating and Corporate Governance, Compliance, and Transaction
committees. Ms.&nbsp;Tomasello received her B.S. in Marketing from the University of Cincinnati and her M.B.A. from Murray State University in Kentucky. We believe Ms.&nbsp;Tomasello is qualified to serve as a member of our Board of Directors
because of her experience serving in various commercial roles in the life sciences industry. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;III Directors (Term Expires at 2025 Annual
Meeting) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Steven Nichtberger, M.D.</I></B> Dr.&nbsp;Nichtberger has served as our Chief Executive Officer, President and Chairman of our
board of directors since our founding in 2017. He is also a senior fellow and adjunct professor at The Wharton School of the University of Pennsylvania and a member of the board of directors of the BioAdvance Greenhouse Fund. Previously,
Dr.&nbsp;Nichtberger served as president, chief executive officer, and a member of the board of directors of Tengion, Inc. from 2004 to 2011. In 2008, his leadership was recognized nationally with the National Ernst&nbsp;&amp; Young Entrepreneur of
the Year Award for emerging companies. Earlier in his career, Dr.&nbsp;Nichtberger served as the head of global marketing for Merck and in various commercial operating roles at the company from 1995 to 2003. He has previously served as a member of
the boards of directors of the Alliance for Regenerative Medicine (as a founding member), Pennsylvania Bio (including as chairman), and Biotechnology Industry Organization. From 2008 to 2019, he was a member of the board of overseers for the School
of Arts&nbsp;&amp; Sciences at the University of Pennsylvania. Dr.&nbsp;Nichtberger received his M.D. from the State University of New York at Buffalo, his B.S. from The Wharton School at the University of Pennsylvania and his B.A. from the
University of Pennsylvania. He completed internship, residency and fellowship in the Department of Medicine and the Division of Cardiology of the Mount Sinai Medical Center in New York. We believe Dr.&nbsp;Nichtberger is qualified to serve as a
member and Chairman of our board of directors because of his scientific and medical background as well as his corporate leadership experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mark
Simon, MBA</I></B><I>.</I> Mr.&nbsp;Simon joined our board of directors in October 2018. He is a Strategic Advisor to the Founder and CEO of Sun Pharmaceutical Industries Ltd., which is the largest pharmaceutical company in India and a board
observer of Sun Pharma Advanced Research Company Ltd., both public companies in India, where Mr. Simon is focused on accelerating their innovation initiatives. He is also a consultant to Stifel Nicolaus&nbsp;&amp; Company (NYSE: SF) and <FONT
STYLE="white-space:nowrap">co-founder</FONT> of Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry that Stifel acquired in 2023. Prior to <FONT STYLE="white-space:nowrap">co-founding</FONT>
Torreya, Mr.&nbsp;Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005 where he covered global pharmaceutical companies with a focus on large-capitalization players in the U.S., Europe and Japan.
Prior to Citigroup, Mr.&nbsp;Simon served as a Managing Director at Robertson Stephens in San Francisco and New York where he was responsible for covering the biotechnology investment banking sector. During his tenure overseeing the group, he was
involved in raising 45% of all biotechnology dollars raised in the U.S. from 1999-2001. Prior to joining the investment banking group, Mr.&nbsp;Simon was a senior biotechnology research analyst at Robertson Stephens, and was named a Wall Street <FONT
STYLE="white-space:nowrap">All-Star</FONT> Analyst for three years in a row. He began his career at Kidder Peabody as a biotechnology research associate in 1984 and participated in the IPO of Genzyme and the early financings of companies such as
Amgen. Mr.&nbsp;Simon currently serves on the board of directors of Portage Biotech Inc. (Nasdaq: PRTG), a public biotechnology company. Mr.&nbsp;Simon also serves on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the boards of directors of several disease advocacy and philanthropic foundations in the oncology, CNS/neuroscience and metabolic areas. He received his MBA from Harvard Business School and his
B.A. from Columbia College. We believe that Mr.&nbsp;Simon is qualified to serve on our board of directors because of his extensive experience of over 35 years in the life sciences industry and biotechnology and specialty pharmaceutical
transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships between or among any of our directors or executive officers. The principal occupation and employment
during the past five years of each of our directors was carried on, in each case except as specifically identified above, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or
understanding between any of our directors and any other person or persons pursuant to which he or she is to be selected as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no
material legal proceedings to which any of our directors is a party adverse to us or in which any such director has a material interest adverse to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Diversity Matrix </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The composition of our board of
directors currently includes two individuals who are diverse under the Nasdaq Stock Market LLC, or Nasdaq, listing rule regarding board diversity, representing gender diversity of 33% and ethnic diversity of 16%, as presented in the below Board
Diversity Matrix. Under the Nasdaq listing rule, directors who self-identify as (i)&nbsp;female, (ii) an underrepresented minority or (iii)&nbsp;LGBTQ+ are defined as being diverse. The following table provides certain self-identified personal
characteristics of our directors, in accordance with Rule 5605(f) of the Nasdaq listing standards: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="16" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Board Diversity Matrix (as of April&nbsp;4,
2024)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><B>Total Number of Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Female</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Male</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">Non-Binary</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Did Not<BR>Disclose<BR>Gender</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part I: Gender Identity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part II: Demographic Background</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">African American or Black</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alaskan Native or Native American</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian (other than South Asian)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">South Asian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hispanic or Latinx</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Native Hawaiian or Pacific Islander</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or More Races or Ethnicities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center">&#151;&#8194;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Did Not Disclose Demographic Background</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center">&#151;&#8194;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_3"></A>PROPOSAL NO. 2 &#150; RATIFICATION OF THE APPOINTMENT OF
ERNST&nbsp;&amp; YOUNG </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS CABALETTA&#146;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FISCAL YEAR ENDING DECEMBER&nbsp;31, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta&#146;s stockholders are being asked to ratify the appointment by the audit committee of the board of directors of Ernst&nbsp;&amp; Young as
Cabaletta&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2024. Ernst&nbsp;&amp; Young has served as Cabaletta&#146;s independent registered public accounting firm since 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee is solely responsible for selecting Cabaletta&#146;s independent registered public accounting firm for the fiscal year ending
December&nbsp;31, 2024. Stockholder approval is not required to appoint Ernst&nbsp;&amp; Young as Cabaletta&#146;s independent registered public accounting firm. However, the board of directors believes that submitting the appointment of
Ernst&nbsp;&amp; Young to the stockholders for ratification is good corporate governance. If the stockholders do not ratify this appointment, the audit committee will reconsider whether to retain Ernst&nbsp;&amp; Young. If the selection of
Ernst&nbsp;&amp; Young is ratified, the audit committee, at its discretion, may direct the appointment of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of Cabaletta
and its stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A representative of Ernst&nbsp;&amp; Young is expected to be present at the Annual Meeting and will have an opportunity to make a
statement if he or she desires to do so and to respond to appropriate questions from our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta incurred the following fees from
Ernst&nbsp;&amp; Young for the audit of the financial statements and for other services provided during the years ended December&nbsp;31, 2023 and 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">830,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">740,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related fees(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">895,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">785,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit fees consist of fees for the audit of our annual financial statements, the review of our interim
financial statements included in our quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> comfort letters and consents. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit-related fees consist of services that are reasonably related to the performance of the audit or review of
our financial statements. There were no such fees incurred in 2023 or 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax Fees consist of fees for tax compliance, advice and tax services. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There were no other fees incurred in 2023 or 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee <FONT STYLE="white-space:nowrap">Pre-approval</FONT> Policy and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit committee has adopted policies and procedures relating to the approval of all audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services
that are to be performed by our independent registered public accounting firm. This policy provides that we will not engage our independent registered public accounting firm to render audit or <FONT STYLE="white-space:nowrap">non-audit</FONT>
services unless the service is specifically approved in advance by our audit committee or the engagement is entered into pursuant to the <FONT STYLE="white-space:nowrap">pre-approval</FONT> procedure described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, our audit committee may <FONT STYLE="white-space:nowrap">pre-approve</FONT> specified types of services that are expected to be provided to
us by our independent registered public accounting firm during the next 12 months. Any such <FONT STYLE="white-space:nowrap">pre-approval</FONT> details the particular service or type of services to be provided and is also generally subject to a
maximum dollar amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During our 2023 and 2022 fiscal years, no services were provided to us by Ernst&nbsp;&amp; Young other than
in accordance with the <FONT STYLE="white-space:nowrap">pre-approval</FONT> policies and procedures described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required; Board
Recommendation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of votes properly cast for and against this Proposal is required to ratify the appointment of
Ernst&nbsp;&amp; Young as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2024. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> if any, will have no effect on the outcome of
the vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Board of Directors recommends voting &#147;FOR&#148; Proposal No.&nbsp;2 to ratify the appointment of Ernst&nbsp;&amp; Young as
Cabaletta&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2024. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_4"></A>CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Nomination Process </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our nominating and corporate
governance committee is responsible for identifying individuals qualified to serve as directors, consistent with criteria approved by our board of directors, and recommending such persons to be nominated for election as directors, except where we
are legally required by contract, law or otherwise to provide third parties with the right to nominate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process followed by our nominating and
corporate governance committee to identify and evaluate director candidates includes requests to board members and others for recommendations, meetings from time to time to evaluate biographical information and background material relating to
potential candidates, and interviews of selected candidates by management, recruiters, members of the committee and our board of directors. The qualifications, qualities and skills that our nominating and corporate governance committee believes must
be met by a committee-recommended nominee for a position on our board of directors are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should demonstrate high standards of personal and professional ethics and integrity.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should have proven achievement and competence in the nominee&#146;s field and the ability to exercise
sound business judgment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should have skills that are complementary to those of the existing board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should have the ability to assist and support management and make significant contributions to the
Company&#146;s success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should have an understanding of the fiduciary responsibilities that are required of a member of the
board of directors and the commitment of time and energy necessary to diligently carry out those responsibilities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders may
recommend individuals to the nominating and corporate governance committee for consideration as potential director candidates. Any such proposals should be submitted to our corporate secretary at our principal executive offices no later than the
close of business on the 90th day nor earlier than the close of business on the 120th day prior to the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of the preceding year&#146;s annual meeting and should include
appropriate biographical and background material to allow the nominating and corporate governance committee to properly evaluate the potential director candidate and the number of shares of our stock beneficially owned by the stockholder proposing
the candidate. Stockholder proposals should be addressed to Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104, Attention: Corporate Secretary. Assuming that biographical and background material has been provided on a timely
basis in accordance with our bylaws, any recommendations received from stockholders will be evaluated in the same manner as potential nominees proposed by the nominating and corporate governance committee. If our board of directors determines to
nominate a stockholder-recommended candidate and recommends his or her election, then his or her name will be included on our proxy card for the next annual meeting of stockholders. See &#147;Stockholder Proposals&#148; for a discussion of
submitting stockholder proposals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicable Nasdaq rules require a majority of a listed company&#146;s board of directors to be comprised of independent directors within one year of listing.
In addition, the Nasdaq rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy
independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act and that compensation committee members satisfy independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under
the Exchange Act. Under applicable Nasdaq rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his
or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or
otherwise be an affiliated person of the listed company or any of its subsidiaries. In addition, in affirmatively determining the independence of any director who will serve on a company&#146;s compensation committee, Rule <FONT
STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act requires that a company&#146;s board of directors must consider all factors specifically relevant to determining whether a director has a relationship to such company which is material
to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including: the source of compensation to the director, including any consulting, advisory or other compensatory fee
paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of
directors has determined that all members of the board of directors, except Dr.&nbsp;Nichtberger are independent directors, including for purposes of the rules of Nasdaq and the SEC. In making such independence determination, our board of directors
considered the relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with us and all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the
beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. In considering the independence of the directors listed above, our board of directors considered the association of our directors with
the holders of more than 5% of our common stock. There are no family relationships among any of our directors or executive officers. Dr.&nbsp;Nichtberger is not an independent director under these rules because he is an executive officer of the
Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Diversity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that diversity
of our directors is an important element of an effective board of directors. The nominating and corporate governance committee&#146;s evaluation of director nominees includes consideration of their ability to contribute to the diversity of personal
and professional experiences, opinions, perspectives and backgrounds on the board of directors. Nominees are not discriminated against based on race, color, religion, sex, ancestry, national origin, sexual orientation, disability or any other basis
prescribed by law. An assessment of the composition and diversity of the board of directors is part of the annual board of directors&#146; self-evaluation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has established
an audit committee, a compensation committee, and a nominating and corporate governance committee. Each of the audit committee, compensation committee, and nominating and corporate governance committee operates under a charter that satisfies the
applicable standards of the SEC and Nasdaq. Our board of directors has also established a science and technology committee, an advisory committee of the board of directors which operates under a charter duly adopted by the board of directors. Each
such committee reviews its respective charter at least annually. A current copy of the charter for each of the audit committee, compensation committee, nominating and corporate governance committee and science and technology committee is posted on
the corporate governance section of our website, <B><I>www.investors.cabalettabio.com/corporate-governance/governance-highlights</I></B>. From time to time, our board of directors may establish certain committees for scientific, business or other
matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott Brun, M.D.,
Richard Henriques, MBA and Mark Simon, MBA serve on the audit committee, which is chaired by Richard Henriques, MBA. Our board of directors has determined that each member of the audit committee is &#147;independent&#148; for audit committee
purposes as that term is defined in the rules of the SEC and the applicable Nasdaq rules, and each has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board of directors has designated Mr.&nbsp;Henriques
as an &#147;audit committee financial expert,&#148; as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defined under the applicable rules of the SEC. During the fiscal year ended December&nbsp;31, 2023, the audit committee met four times. The report of the audit committee is included in this proxy
statement under &#147;Report of the Audit Committee.&#148; The audit committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public
accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and
quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent
registered public accounting firm whether our audited financial statements and our related disclosures under the &#147;Management&#146;s Discussion and Analysis&#148; section shall be included in our 2023 Annual Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as
they relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing quarterly earnings releases; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the Company&#146;s risk assessment and management guidelines, including the Company&#146;s major
financial risk exposures, cybersecurity risks and the steps that the Company&#146;s management has taken to monitor and control such exposures and risks. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services, other than <I>de minimis </I><FONT STYLE="white-space:nowrap">non-audit</FONT>
services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Henriques, MBA,
Mark Simon, MBA and Shawn Tomasello, MBA serve on the compensation committee, which is chaired by Mark Simon, MBA. Our board of directors has determined that each member of the compensation committee is &#147;independent&#148; as defined in the
applicable Nasdaq rules. During the fiscal year ended December&nbsp;31, 2023, the compensation committee met four times. The compensation committee&#146;s responsibilities include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annually reviewing and recommending to the board of directors corporate goals and objectives relevant to the
compensation of our chief executive officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the performance of our chief executive officer in light of such corporate goals and objectives and
based on such evaluation (i)&nbsp;recommending to the board of directors the cash compensation of our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
chief executive officer and (ii)&nbsp;reviewing and approving grants and awards to our chief executive officer under equity-based plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing our overall management compensation, philosophy, and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence
standards identified in the applicable Nasdaq rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to our board of directors about our policies and procedures for the grant of
equity-based awards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the compensation committee report required by SEC rules, if and when required, to be included in our
annual proxy statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; if and
when required, to be included in our annual proxy statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the
evaluation of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Bollard, MBChB, M.D., Scott Brun, M.D., and Mark Simon, MBA, serve on the nominating and corporate governance committee, which is chaired by Scott
Brun, M.D. Our board of directors has determined that each member of the nominating and corporate governance committee is &#147;independent&#148; as defined in the applicable Nasdaq rules. During the fiscal year ended December&nbsp;31, 2023, the
nominating and corporate governance committee met two times. The nominating and corporate governance committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees
recommended by stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the
appropriate skills and expertise to advise us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with the board of directors corporate succession plans for our chief executive officer
and other key officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the board of directors a code of business conduct and ethics and a set of
corporate governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the evaluation of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee considers candidates for board of directors membership suggested by its members and the chief executive
officer. Additionally, in selecting nominees for directors, the nominating and corporate governance committee will review candidates recommended by stockholders in the same manner and using the same general criteria as candidates recruited by the
committee and/or recommended by our board of directors. Any stockholder who wishes to recommend a candidate for consideration by the committee as a nominee for director should follow the procedures described later in this proxy statement under
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the heading &#147;Stockholder Proposals.&#148; The nominating and corporate governance committee will also consider whether to nominate any person proposed by a stockholder in accordance with the
provisions of our bylaws relating to stockholder nominations as described later in this proxy statement under the heading &#147;Stockholder Proposals.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Identifying and Evaluating Director Nominees.</I> Our board of directors is responsible for filling vacancies on our board of directors and for nominating
candidates for election by our stockholders each year in the class of directors whose term expires at the relevant annual meeting. The board of directors delegates the selection and nomination process to the nominating and corporate governance
committee, with the expectation that other members of the board of directors, and of management, will be requested to take part in the process as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the nominating and corporate governance committee identifies candidates for director nominees in consultation with management, through the
recommendations submitted by stockholders or through such other methods as the nominating and corporate governance committee deems to be helpful to identify candidates. Once candidates have been identified, the nominating and corporate governance
committee confirms that the candidates meet all of the minimum qualifications for director nominees established by the nominating and corporate governance committee. The nominating and corporate governance committee may gather information about the
candidates through interviews, detailed questionnaires, comprehensive background checks or any other means that the nominating and corporate governance committee deems to be appropriate in the evaluation process. The nominating and corporate
governance committee then meets as a group to discuss and evaluate the qualities and skills of each candidate, both on an individual basis and taking into account the overall composition and needs of our board of directors. Based on the results of
the evaluation process, the nominating and corporate governance committee recommends candidates for the board of directors&#146; approval to fill a vacancy or as director nominees for election to the board of directors by our stockholders each year
in the class of directors whose term expires at the relevant annual meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Science&nbsp;and&nbsp;Technology&nbsp;Committee</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Bollard, MBChB, M.D., Scott Brun, M.D., and Shawn Tomasello, MBA, serve on the science and technology committee, which is chaired by Catherine
Bollard, MBChB, M.D. The science and technology committee supports Board oversight of the Company&#146;s research and development, manufacturing and supply activities, by providing a forum for review of strategic considerations and issues in such
areas, as well as to evaluate relevant emerging technology and advances in the field. The science and technology committee was formed in July 2023 and held two meetings in during the fiscal year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board and Committee Meetings Attendance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full board
of directors met nine times during 2023. During 2023, each member of the board of directors attended in person or participated in 75% or more of the aggregate of (i)&nbsp;the total number of meetings of the board of directors (held during the period
for which such person has been a director) and (ii)&nbsp;the total number of meetings held by all committees of the board of directors on which such person served (during the periods that such person served). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Attendance at Annual Meeting of Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors are responsible for attending the annual meeting of stockholders to the extent practicable. Four out of five of our directors then in office attended
our 2023 annual meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy on Trading, Pledging and Hedging of Company Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain transactions in our securities (such as purchases and sales of publicly traded put and call options, and short sales) create a heightened compliance
risk or could create the appearance of misalignment between </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management and stockholders. In addition, securities held in a margin account or pledged as collateral may be sold without consent if the owner fails to meet a margin call or defaults on the
loan, thus creating the risk that a sale may occur at a time when an officer or director is aware of material, <FONT STYLE="white-space:nowrap">non-public</FONT> information or otherwise is not permitted to trade in Company securities. Our insider
trading policy expressly prohibits short sales and derivative transactions of our stock by our executive officers, directors, employees and certain designated consultants and contractors, including short sales of our securities. Our insider trading
policy expressly prohibits, without the advance approval of our audit committee, purchases or sales of puts, calls, or other derivative securities of the company or any derivative securities that provide the economic equivalent of ownership. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Catherine Bollard, MBChB, M.D., Richard Henriques, Mark Simon, and Shawn Tomasello, served on the compensation committee during fiscal year 2023. No
member of the compensation committee has ever been an officer or employee of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our executive officers serve, or have served during the
last fiscal year, as a member of the board of directors, compensation committee, or other board committee performing equivalent functions of any other entity that has one or more executive officers serving as one of our directors or on our
compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer,
principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the corporate governance section of our website, which is located at
<B><I>www.cabalettabio.com/investors/corporate-governance/governance-documents</I></B>. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the
nature of such amendment or waiver on our website or in a current report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership
Structure and Board&#146;s Role in Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that effective board leadership structure can depend on the experience, skills, and
personal interaction between persons in leadership roles and the needs of our company at any point in time. Our corporate governance guidelines support flexibility in the structure the board of directors by not requiring the separation of the roles
of chairman of the board of directors and chief executive officer. Our board of directors currently believes that it is in the best interests of our company to have our chief executive officer also serve as the chairman of the board of directors. We
believe that our chairman and chief executive officer provides strong, clear, and unified leadership that is critical in our relationships with our shareholders, employees, customers, suppliers, and other stakeholders. The extensive knowledge of the
chief executive officer regarding our operations and industries and the markets in which we compete uniquely positions him to identify strategies and prioritize matters for board review and deliberation. Additionally, we believe the combined role of
chairman and chief executive officer facilitates centralized board leadership in one person, so there is no ambiguity about accountability. The chief executive officer serves as a bridge between management and the board of directors, ensuring that
both groups act with a common purpose. This structure also eliminates conflict between two leaders and minimizes the possibility of two spokespersons sending difference messages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors does not believe that combining the position creates significant risks, including any risk that the chairman and chief executive
officer will have excessive or undue influence over the agenda or deliberations of the board of directors. We believe we have effective and active oversight by experienced independent directors and independent committee chairs, and the independent
directors meet together in executive session at virtually every board of directors meeting. The chairman of the board of directors provides guidance to the board of directors; facilitates an appropriate schedule for board of directors meetings; sets
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agenda for board of directors meetings; presides over meetings of the board of directors; and facilitates the quality, quantity, and timeliness of the flow of information from management that is
necessary for the board to effectively and responsibly perform its duties. The chief executive officer is responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> leadership of our company and
setting our company&#146;s strategic direction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risk is inherent to every business, and how well a business manages risk can ultimately determine its
success. We face a number of risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction, and intellectual property. Management is responsible for the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its
risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of directors, as disclosed
in the descriptions of each of the committees above and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a particular committee) discusses
with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairman of the
relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk oversight role, particularly
with respect to risk interrelationships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Communication with the Directors of Cabaletta </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any interested party with concerns about our company may report such concerns to the board of directors or the chairman of our board of directors or the
chairman of our nominating and corporate governance committee, by submitting a written communication to the attention of such director at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">c/o Cabaletta Bio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2929 Arch
Street, Suite 600 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Philadelphia, PA 19104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United States </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may submit your concern
anonymously or confidentially by postal mail. You may also indicate whether you are a stockholder, customer, supplier, or other interested party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy
of any such written communication may also be forwarded to Cabaletta&#146;s legal counsel and a copy of such communication may be retained for a reasonable period of time. The director may discuss the matter with Cabaletta&#146;s legal counsel, with
independent advisors, with <FONT STYLE="white-space:nowrap">non-management</FONT> directors, or with Cabaletta&#146;s management, or may take other action or no action as the director determines in good faith, using reasonable judgment, and applying
his or her own discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Communications may be forwarded to other directors if they relate to important substantive matters and include suggestions or
comments that may be important for other directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs,
personal grievances, and matters as to which we tend to receive repetitive or duplicative communications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee oversees the procedures for
the receipt, retention, and treatment of complaints received by Cabaletta regarding accounting, internal accounting controls, or audit matters, and the confidential, anonymous submission by employees of concerns regarding questionable accounting,
internal accounting controls or auditing matters. Cabaletta has also established a toll-free telephone number for the reporting of such activity, which
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-800-916-7037</FONT></FONT></FONT> (company identifier: 2222). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_5"></A>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table identifies our executive officers, and sets forth their current positions at Cabaletta and their ages as of April&nbsp;4, 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position Held with Cabaletta</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Officer<BR>Since</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer, President, Chairman of the Board of Directors and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gwendolyn K. Binder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President, Science and Technology</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anup Marda, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Chang, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Gerard, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General Counsel and Secretary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arun Das, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Business Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should refer to &#147;<I>Class</I><I></I><I>&nbsp;III Directors</I>&#148; above for information about our Chief Executive
Officer and President, Dr.&nbsp;Nichtberger. Biographical information for our other executive officers, as of April&nbsp;4, 2024, is set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gwendolyn K. Binder, Ph.D.</I></B> Dr.&nbsp;Binder joined our company in February 2019 as our Executive Vice President, Science and Technology and was
appointed President, Science and Technology in January 2022. Dr.&nbsp;Binder is an R&amp;D executive with specialized expertise in the discovery and early clinical development and optimization of engineered T cell therapies. Prior to joining
Cabaletta, Dr.&nbsp;Binder was the Chief Technology Officer of Adaptimmune Therapeutics Plc from March 2016 to January 2019, where she ultimately led the research team focusing on understanding mechanisms of tumor response and resistance and
translating this understanding to next generation products and clinical study designs. In prior roles, from March 2011 to February 2016, she established and led the translational research group, in addition to the manufacturing and quality teams
including oversight of the buildout of an <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing facility. Earlier in her career, Dr.&nbsp;Binder served as Director of Operations for the Translational Research Program at the University of
Pennsylvania, where she where she progressed multiple investigational new drug submissions for novel engineered <FONT STYLE="white-space:nowrap">T-cell</FONT> therapies in HIV and oncology, including the CD19 CAR IND acquired by Novartis (now
Kymriah), the first human gene editing IND, and three TCR engineered T cell therapy studies in oncology and HIV. Prior to that, she served as the Director of Scientific Affairs at VIRxSYS Corporation in Gaithersburg Maryland where she supported the
development of the first clinical lentiviral vector used in humans, for the application of engineered T cell therapy for HIV. In addition, Dr.&nbsp;Binder has served on the Board of Directors of Instil Bio (Nasdaq: TIL), a company developing tumor
infiltrating lymphocytes for cancer immunotherapy, since July 2020, and as a member of the Scientific Advisory Board for Immatics, which is a publicly traded company developing engineered T cell immunotherapy for cancer, since July 2020.
Dr.&nbsp;Binder studied viral immunology and translational research at the Johns Hopkins University in Baltimore, Maryland where she earned a Ph.D. in Cellular and Molecular Medicine in 2002. She has authored over 30 publications in the field,
including top international journals such as &#147;Science&#148;, and &#147;Nature Medicine&#148;. She is a recognized leader in the biotechnology sector for the translational and clinical advancement of novel T cell therapies for patients with
serious diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anup Marda, MBA.</I></B> Mr.&nbsp;Marda joined our company in January 2019 as our Chief Financial Officer. From April 2001 to
January 2019, Mr.&nbsp;Marda held positions at Bristol-Myers Squibb, including, most recently, as Vice President, Head of Global Corporate Financial Planning&nbsp;&amp; Analysis, and previously as Head of Finance, R&amp;D Operations and Head of
Finance, R&amp;D Portfolio Management and Global Medical from 2014 to 2018. Prior to this, Mr.&nbsp;Marda held the role of Executive Director, U.S. Pharmaceuticals from 2012 to 2014 and Assistant Treasurer, Capital Markets from 2008 to 2012.
Mr.&nbsp;Marda received his MBA from the Krannert School of Business of Purdue University and his B.Tech in Chemical Engineering from the Indian Institute of Technology Bombay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>David J. Chang, M.D., M.P.H.</I></B> Dr.&nbsp;Chang joined our company in June 2019 as our Chief Medical Officer. From June 2015 to May 2019, he was
Senior Vice President and Head, Inflammation, Autoimmunity&nbsp;&amp; Neuroscience, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or IA&amp;NS, Global Medicines Development at AstraZeneca Pharmaceuticals LP, where he oversaw development projects of both biologics and small molecules in a variety of indications and led the
late-stage clinical development organization for IA&amp;NS. From October 2007 to June 2015, Dr.&nbsp;Chang served in various positions at GlaxoSmithKline plc, including VP and Head, Immuno-Inflammation, Clinical Development. While at AstraZeneca and
GlaxoSmithKline, he provided leadership in driving the clinical development and registration of the only two products approved for systemic lupus erythematosus in the US in over 60 years. He received his M.D. from New York University School of
Medicine, his M.P.H. from Emory University and his B.S. from Yale University. Dr.&nbsp;Chang completed his internship and residency in internal medicine at the New York Hospital&#151;Cornell University Medical Center and fellowship in rheumatology
at the Hospital for Special Surgery&#151;Cornell University Medical Center. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael Gerard, J.D. </I></B>Mr.&nbsp;Gerard joined our company in
September 2021 as our General Counsel and Secretary. Prior to joining Cabaletta, Mr.&nbsp;Gerard served as Associate General Counsel of Spark Therapeutics, Inc., or Spark, from September 2020 to August 2021. Prior to Spark, Mr.&nbsp;Gerard served in
various legal roles at Sandoz, Inc., a division of the Novartis Group, beginning in 2013, with the most recent role being Executive Director, Associate General Counsel, Business Development and Licensing, Strategy and Portfolio. Earlier in his
career, Mr.&nbsp;Gerard served as Assistant General Counsel at Aramark and as a litigator at the law firms of Morrison&nbsp;&amp; Foerster, LLP and K&amp;L Gates, LLP in New York. Mr.&nbsp;Gerard received a B.A. in Political Science from the
University of Michigan, Ann Arbor and a J.D. from Cornell Law School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Arun Das, M.D.</I></B> Dr.&nbsp;Das joined our company in July 2019 after
serving as a consultant to the company since 2017, and served in several roles, most recently Executive Director of New Product Planning and Business Development, prior to being appointed Chief Business Officer in January 2022. He is also a Lecturer
in the Health Care Management Department at the Wharton School of the University of Pennsylvania. Prior to joining Cabaletta, Dr.&nbsp;Das was a resident physician in General Pediatrics at the Children&#146;s Hospital of Philadelphia from June 2018
to June 2019. Previously, he was an investment banking analyst in the healthcare group at Goldman Sachs from 2010 to 2012. In addition, Dr.&nbsp;Das has spent multiple years consulting in business development and operations for several <FONT
STYLE="white-space:nowrap">start-ups</FONT> in the biotechnology space. Dr.&nbsp;Das received his M.D. from Johns Hopkins University School of Medicine and a B.A. and B.S. dual degree from the University of Pennsylvania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal occupation and employment during the past five years of each of our executive officers was carried on, in each case except as specifically
identified above, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our executive officers and any other person or persons pursuant to which he or
she was or is to be selected as an executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no material legal proceedings to which any of our executive officers is a party adverse
to us or in which any such executive officer has a material interest adverse to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_6"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our named executive officers for the year ended December&nbsp;31, 2023 are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Steven Nichtberger, M.D., our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gwendolyn Binder, Ph.D., our President, Science and Technology; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David J. Chang, M.D., M.P.H., our Chief Medical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2023 Summary Compensation Table </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table presents the compensation awarded to, earned by or paid to each of our named executive officers for the years indicated. Dr.&nbsp;Nichtberger also serves as a member of our board of directors but does not receive any additional compensation
for his service as a director. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">597,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,784,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,808,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">568,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">839,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,809,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gwendolyn K. Binder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">477,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,618,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,340,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President, Science and Technology</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">461,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">353,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,046,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Chang, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">476,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,379,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,101,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">298,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">974,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the grant date fair value of option awards granted in 2023 and 2022 in accordance with the
Financial Accounting Standards Board&#146;s Accounting Standards Codification Topic 718, or ASC 718. Such grant date fair value does not take into account any estimated forfeitures related to service-vesting conditions. For information regarding
assumptions underlying the valuation of equity awards, see Note 9 to our financial statements for the year ended December&nbsp;31, 2023. These amounts do not correspond to the actual value that may be recognized by the named executive officers upon
vesting of applicable awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts represent bonuses earned in 2023 and 2022 and paid in 2024 and 2023, respectively, pursuant to the
Company&#146;s cash incentive plan based on the factors described under <FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount includes reimbursements for life insurance premiums. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Narrative to 2023 Summary Compensation Table </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
board of directors and compensation committee review compensation annually for our chief executive officer and his direct reports. In setting executive base salaries and bonuses, and granting equity incentive awards, our board of directors considers
compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve <FONT
STYLE="white-space:nowrap">short-and</FONT> long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We target a general competitive position, based on independent third-party benchmark
analytics to inform the mix of compensation of base salary, bonus or long-term incentives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has historically determined our
executives&#146; compensation. Our compensation committee typically reviews and discusses management&#146;s proposed compensation with the chief executive officer for all of his direct reports. Based on those discussions and its discretion, taking
into account the factors noted above, the compensation committee determines the compensation for each executive officer other than the chief executive officer. Our board of directors discusses the compensation committee&#146;s recommendations and
ultimately approves the compensation of our chief executive officer without the chief executive officer and chief financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officer present. In 2023, the compensation committee continued to retain the services of Radford, an AON Hewitt company, as its external compensation consultant and the board of directors and the
compensation committee considered Radford&#146;s input on certain compensation matters as they deemed appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual base salary </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each named executive officer&#146;s base salary is a fixed component of annual compensation for performing specific duties and functions, and has been
established by our board of directors taking into account each individual&#146;s role, responsibilities, skills, and experience. Base salaries for our named executive officers are reviewed annually by our compensation committee, typically in
connection with our annual performance review process, and adjusted from time to time, based on the recommendation of the compensation committee, to realign salaries with market levels after taking into account individual responsibilities,
performance, and experience. The base salary of each named executive officer is noted below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023&nbsp;Base&nbsp;Salary<BR>through<BR>February&nbsp;28,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023&nbsp;Base&nbsp;Salary<BR>effective<BR>March&nbsp;1, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">573,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$602,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gwendolyn K. Binder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">462,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$480,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Chang, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">461,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$480,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual cash awards are determined based on company performance, which is assessed based on predetermined annual objectives, and on individual performance. When
determining the individual component of our annual incentive awards, the compensation committee considers each executive&#146;s contributions to the company&#146;s strategic achievements and financial and operational performance. In addition, the
compensation committee considers how each executive demonstrates Cabaletta behaviors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our named executive officers was eligible to receive a
bonus with respect to 2023 as a percentage of base salary listed below, modified by company and individual performance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023&nbsp;Target&nbsp;Bonus<BR>Rate<BR>(% of base salary)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gwendolyn K. Binder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Chang, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company performance was assessed as achievement of 2023 company objectives, including certain pipeline and development
milestones, execution of manufacturing, clinical and compliance processes and partnerships, the achievement of financing and business development milestones and development of a strong team culture. As a result, the compensation committee
recommended and our board of directors approved 2023 company achievement at 107%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation committee recommended (and/or approved) and the board
of directors approved (as applicable, in the instance of the chief executive officer), a further adjustment of bonuses based on the individual achievement of each of the named executive officers, as noted below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Individual<BR>Achievement<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gwendolyn K. Binder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Chang, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Long-term equity incentives </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our equity grant program is intended to align the interests of our named executive officers with those of our stockholders and to motivate them to make
important contributions to our performance. In 2023, we granted stock options to each of our named executive officers, as reflected in the &#147;Outstanding Equity Awards at 2023 Fiscal Year End Table&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment arrangements with our named executive officers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2019, we entered into amended and restated employment agreements with each of our named executive officers. Each of our named executive officers is
employed at will. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Steven Nichtberger, M.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under his amended and restated employment agreement, Dr.&nbsp;Nichtberger is entitled to an annual base salary, which is subject to review and redetermination
by our board of directors or our compensation committee, and he is eligible to receive an annual bonus determined by our board of directors or the compensation committee (subject to the terms of any applicable incentive compensation plan that may be
in effect from time to time), targeted at 55% of his annual base salary. Dr.&nbsp;Nichtberger is also eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans, and is reimbursed for his
existing, personal life insurance policy premiums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Nichtberger&#146;s employment agreement provides that, in the event that his employment is
terminated by us without &#147;cause&#148; or by him for &#147;good reason,&#148; then subject to the execution and effectiveness of a separation agreement and release and compliance with his continuing obligations, he will be entitled to receive
(i)&nbsp;an amount equal to (x) 12 months of base salary payable on our normal payroll cycle if such termination occurs outside of the period commencing 60 days before and ending 12 months after the occurrence of the first event constituting a
&#147;change in control&#148;, or the Change in Control Period, or (y) 1.5 times the sum of his base salary plus his target bonus for the then-current year payable on our or our successor&#146;s normal payroll cycle over 18 months if such
termination occurs within Change in Control Period; (ii)&nbsp;payment of the monthly employer COBRA premium for the same level of group health coverage as in effect for Dr.&nbsp;Nichtberger on the date of termination for up to (x) 12 months if such
termination occurs outside of the Change in Control Period, and (y) 18 months if such termination occurs within the Change in Control Period; and (iii)&nbsp;full acceleration of all stock options and other stock-based awards held by
Dr.&nbsp;Nichtberger if such termination occurs within the Change in Control Period. In addition to standard good reason triggers, Dr.&nbsp;Nichtberger may elect to resign for good reason if within six months following the appointment of a
chairperson of the board of directors, Dr.&nbsp;Nichtberger provides written notice of his reasonable dissatisfaction with such chairperson and the board fails to designate a new chairperson within 30 days of such notice. In the event of such a
resignation for good reason outside of the Change in Control Period, subject to the execution and effectiveness of a separation agreement and release and compliance with his continuing obligations, in addition to the severance benefits described
above, all stock options and other stock-based awards held by Dr.&nbsp;Nichtberger will accelerate and become fully exercisable or nonforfeitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
payments and benefits provided to Dr.&nbsp;Nichtberger under his employment agreement in connection with a sale event may not be eligible for a federal income tax deduction for the company pursuant to Section&nbsp;280G of the Code. These payments
and benefits also may be subject to an excise tax under Section&nbsp;4999 of the Code. If the payments or benefits payable to Dr.&nbsp;Nichtberger in connection with a sale event would be subject to the excise tax on golden parachutes imposed under
Section&nbsp;4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after tax benefit to Dr.&nbsp;Nichtberger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Dr.&nbsp;Nichtberger has entered into a <FONT STYLE="white-space:nowrap">non-competition,</FONT>
<FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality and assignment agreement with us that contains, among other things, <FONT STYLE="white-space:nowrap">non-competition</FONT> and
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions that apply during the term of Dr.&nbsp;Nichtberger&#146;s employment and for 12 months thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gwendolyn K. Binder, Ph.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under her amended and restated employment agreement, Dr.&nbsp;Binder is entitled to an annual base salary, which is subject to review and redetermination by
our board of directors or our compensation committee, and she is eligible to earn an annual bonus with a target amount equal to 40% of her base salary. Dr.&nbsp;Binder is also eligible to participate in the employee benefit plans available to our
employees, subject to the terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Binder&#146;s employment agreement provides that, in the event that her employment is terminated
by us without &#147;cause&#148; or by her for &#147;good reason,&#148; then subject to the execution and effectiveness of a separation agreement and release and compliance with her continuing obligations, she will be entitled to receive (i)&nbsp;an
amount equal to (x)&nbsp;nine months of base salary payable on our normal payroll cycle if such termination occurs outside of the Change in Control Period or (y)&nbsp;a lump sum in cash in the amount of 1.0 times the sum of her base salary plus her
target bonus for the then-current year payable on our or our successor&#146;s normal payroll cycle over 12 months if such termination is occurs within the Change in Control Period; (ii)&nbsp;payment of the monthly employer COBRA premium for the same
level of group health coverage as in effect for Dr.&nbsp;Binder on the date of termination up to (x)&nbsp;nine months if such termination occurs outside of the Change in Control Period, and (y) 12 months if such termination occurs within the Change
in Control Period; and (iii)&nbsp;full acceleration of all stock options and other stock-based awards subject to time-based vesting held by Dr.&nbsp;Binder if such termination occurs within the Change in Control Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The payments and benefits provided to Dr.&nbsp;Binder under her employment agreement in connection with a sale event may not be eligible for a federal income
tax deduction for the company pursuant to Section&nbsp;280G of the Code. These payments and benefits also may be subject to an excise tax under Section&nbsp;4999 of the Code. If the payments or benefits payable to Dr.&nbsp;Binder in connection with
a sale event would be subject to the excise tax on golden parachutes imposed under Section&nbsp;4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net
<FONT STYLE="white-space:nowrap">after-tax</FONT> benefit to such officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Dr.&nbsp;Binder has entered into a
<FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality and assignment agreement with us that contains, among other things,
<FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions that apply during the term of Dr.&nbsp;Binder&#146;s employment and for 12 months thereafter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>David J. Chang, M.D., M.P.H. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under his amended
and restated employment agreement, Dr.&nbsp;Chang is entitled to an annual base salary, which is subject to review and redetermination by our board of directors or our compensation committee, and he is eligible to earn an annual bonus with a target
amount equal to 40% of his base salary. Dr.&nbsp;Chang is also eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Chang&#146;s employment agreement provides that, in the event that his employment is terminated by us without &#147;cause&#148; or by him for
&#147;good reason,&#148; then subject to the execution and effectiveness of a separation agreement and release and compliance with his continuing obligations, he will be entitled to receive (i)&nbsp;an amount equal to (x)&nbsp;nine months of base
salary payable on our normal payroll cycle if such termination occurs outside of the Change in Control Period or (y)&nbsp;a lump sum in cash in the amount of 1.0 times the sum of his base salary plus his target bonus for the then-current year
payable on our or our successor&#146;s normal payroll cycle over 12 months if such termination occurs within the Change in Control Period; (ii)&nbsp;payment of the monthly employer COBRA premium for the same level of group health coverage as in
effect for Dr.&nbsp;Chang on the date of termination up to (x)&nbsp;nine months if such termination occurs outside of the Change in Control Period, and (y) 12 months if such termination occurs outside of the Change in Control Period; and
(iii)&nbsp;full acceleration of all stock options and other stock-based awards subject to time-based vesting held by Dr.&nbsp;Chang if such termination occurs within the Change in Control Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The payments and benefits provided to Dr.&nbsp;Chang under his employment agreement in connection with a sale event may not be eligible for a federal income
tax deduction for the company pursuant to Section&nbsp;280G of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Code. These payments and benefits also may be subject to an excise tax under Section&nbsp;4999 of the Code. If the payments or benefits payable to Dr.&nbsp;Chang in connection with a sale event
would be subject to the excise tax on golden parachutes imposed under Section&nbsp;4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net <FONT STYLE="white-space:nowrap">after-tax</FONT>
benefit to such officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Dr.&nbsp;Chang has entered into a <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT
STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality and assignment agreement with us that contains, among other things, <FONT STYLE="white-space:nowrap">non-competition</FONT> and
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions that apply during the term of Dr.&nbsp;Chang&#146;s employment and for 12 months thereafter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Equity Awards at 2023 Fiscal Year End Table </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information regarding all outstanding stock awards and stock options held by each of our named executive officers as of
December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares<BR>or Units<BR>of Stock<BR>that&nbsp;Have<BR>Not<BR>Vested&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value&nbsp;of<BR>Shares or<BR>Units of<BR>Stock<BR>that&nbsp;Have<BR>Not<BR>Vested&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/28/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/28/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/23/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/28/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,219</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/28/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213,750</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/17/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">411,600</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/17/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gwendolyn K. Binder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/28/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/21/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/23/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,062</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/28/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/17/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,000</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/17/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Chang, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/23/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/23/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,390</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/28/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,469</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/28/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,937</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/17/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/17/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest over four years, with 25% vesting on October&nbsp;11, 2019, and the remaining shares vesting
in 36 equal monthly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest over four years, with 25% vesting on October&nbsp;24, 2020, and the remaining shares vesting
in 12 equal quarterly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest over four years, with 25% vesting on March&nbsp;1, 2021, and the remaining shares vesting in
12 equal quarterly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest over four years, with 25% vesting on October&nbsp;11, 2019 and the remaining shares vesting
in 12 equal quarterly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest over four years, with 25% vesting on August&nbsp;22, 2020, and the remaining shares vesting
in 12 equal quarterly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest over four years, with 25% vesting on June&nbsp;17, 2020, and the remaining shares vesting in
12 equal quarterly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest over four years, with 25% vesting on March&nbsp;1, 2022, and the remaining shares vesting in
12 equal quarterly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest over four years, with 25% vesting on January&nbsp;18, 2023, and the remaining shares vesting
in 12 equal quarterly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest over four years, with 25% vesting on January&nbsp;18, 2024, and the remaining shares vesting
in 12 equal quarterly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Narrative
Disclosure </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>401(k) Savings Plan. </I>We participate in a retirement savings plan, or 401(k) plan, that is intended to qualify for favorable tax
treatment under Section&nbsp;401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. U.S. employees who are at least 21 years of age are generally eligible to
participate in the 401(k) plan, subject to certain criteria. Participants may make <FONT STYLE="white-space:nowrap">pre-tax</FONT> and certain <FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) salary deferral contributions to the plan from
their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for <FONT STYLE="white-space:nowrap">catch-up</FONT>
contributions. Participant contributions are held in trust as required by law. An employee&#146;s interest in his or her salary deferral contributions is 100% vested when contributed. We have the ability to make discretionary contributions under the
plan and all eligible employees will receive a Safe Harbor matching contribution up to 4% of eligible pay for the 2023 plan year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Health and Welfare
Benefits</I>. All of our full-time employees, including our executive officers are eligible to participate in certain medical, disability and life insurance benefit programs offered by us. We pay the premiums for term life insurance and long-term
disability for all of our employees, including our executive officers. We also provide all employees, including executive officers, with a flexible spending account plan and paid time off benefits including, vacation, sick time and holidays. We do
not sponsor any qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> defined benefit plans for any of our employees or executives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Risk Assessment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that although a
portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. Our compensation programs are designed to encourage
our executive officers and other employees to remain focused on both short-term and long-term strategic goals, in particular in connection with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT>
compensation philosophy. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plan Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table provides information as of December&nbsp;31, 2023 regarding shares of common stock that may be issued under our equity compensation plans, consisting of the 2018 Stock Option and Grant Plan (the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;2018 Plan&#148;), the 2019 Stock Option and Incentive Plan (the &#147;2019 Plan&#148;) and the 2019&nbsp;Employee Stock Purchase Plan (the &#147;ESPP&#148;). We have no equity compensation
plans that were not approved by security holders. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>to be issued<BR>upon<BR>exercise of<BR>outstanding<BR>options,<BR>units and<BR>rights (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average<BR>exercise<BR>price of<BR>outstanding<BR>options,<BR>units and<BR>rights ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>remaining<BR>available for<BR>future<BR>issuance<BR>under
equity<BR>compensation<BR>plan<BR>(excluding<BR>securities<BR>referenced in<BR>first column)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,141,035</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,139,499</TD>
<TD NOWRAP VALIGN="bottom">(3)(4)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,141,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,139,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of our 2019 Stock Option and Incentive Plan, 2018 Stock Option and Grant Plan, and 2019 Employee Stock
Purchase Plan. Following our initial public offering, we have not and will not grant any awards under our 2018 Stock Option and Grant Plan, but all outstanding awards under the 2018 Stock Option and Grant Plan will continue to be governed by their
existing terms. The shares of common stock underlying any awards granted under the 2018 Stock Option and Grant Plan or 2019 Stock Option and Incentive Plan that are forfeited, canceled, reacquired by us prior to vesting, satisfied without the
issuance of stock, or otherwise terminated (other than by exercise) and the shares of common stock that are withheld upon exercise of a stock option or settlement of such award to cover the exercise price or tax withholding will be added to the
shares of common stock available for issuance under the 2019 Stock Option and Incentive Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 8,141,035 shares of common stock issuable upon the exercise of outstanding options, of which 1,265,991
are subject to our 2018 Stock Option and Grant Plan and 6,875,044 are subject to our 2019 Stock Option and Incentive Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2023, there were 2,767,184 shares available for grant under the 2019 Stock Option and
Incentive Plan and 372,315 shares available for grants under the 2019 Employee Stock Purchase Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The 2019 Stock Option and Incentive Plan provides that the number of shares reserved and available for issuance
under the plan will automatically increase each January&nbsp;1, beginning on January&nbsp;1, 2020, by 4% of the outstanding number of shares of our common stock on the immediately preceding December 31. The 2019 Employee Stock Purchase Plan provides
that the number of shares reserved and available for issuance will automatically increase each January&nbsp;1, beginning on January&nbsp;1, 2020, through January&nbsp;1, 2029, by the least of 234,229 shares of our common stock, 1% of the outstanding
number of shares of our common stock on the immediately preceding December&nbsp;31, or such lesser number of shares as determined by our compensation committee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_7"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation for each person who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our board
of directors and received compensation for such service during the fiscal year ended December&nbsp;31, 2023. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or <FONT
STYLE="white-space:nowrap">non-equity</FONT> awards to, or pay any other compensation to any of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors in 2023. We reimburse members of our board of directors for
reasonable travel expenses. Dr.&nbsp;Nichtberger, our Chief Executive Officer and President, did not receive any compensation for his service as a member and Chairman of our board of directors in 2023. Dr.&nbsp;Nichtberger&#146;s compensation for
service as an employee for fiscal years 2023 and 2022 is presented in &#147;Executive Compensation&#151;2023 Summary Compensation Table.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid<BR>In Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>(1)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Catherine Bollard, MBChB, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Brun, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Henriques, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">259,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Simon, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">260,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn Tomasello, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">486,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">509,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount shown reflects the grant date fair value of an option award granted during 2023. The grant date fair
value was computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation, or FASB ASC Topic 718, disregarding the effect of estimated forfeitures related to
service-based vesting. See Note 9 to the financial statements in our 2023 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> regarding assumptions we made in determining the fair value of option awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2023, the aggregate number of shares subject to option awards held by our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors were: Dr.&nbsp;Bollard: 112,428; Dr.&nbsp;Brun: 88,000; Mr.&nbsp;Henriques: 112,428; Mr.&nbsp;Simon: 112,428 and Ms.&nbsp;Tomasello 44,000. As of December&nbsp;31, 2023, the aggregate number
of unvested shares outstanding held by our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors were: Dr.&nbsp;Bollard: 22,000; Dr.&nbsp;Brun: 22,000; Mr.&nbsp;Henriques: 22,000; Mr.&nbsp;Simon: 22,000 and Ms.&nbsp;Tomasello 40,333.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our initial public offering, we adopted a formal director compensation policy, or the director compensation policy. We amended the director
compensation policy in February 2020 and December 2021, and in July 2023, we amended the director compensation policy to incorporate cash retainers for service on our science and technology committee. Under our director compensation policy, we pay
our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors a cash retainer for service on the board of directors and for service on each committee on which the director is a member. The chairman of each committee receives a higher retainer
for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment is prorated for any portion of such quarter that the director is not serving on our
board of directors. The fees paid to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on the board of directors and for service on each committee of the board of directors on which the director is a member for 2023 are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Member<BR>Annual<BR>Retainer&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Chairperson<BR>Annual<BR>Retainer ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Science and Technology Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, we further amended the director compensation policy, with such amendment to be effective
as of January&nbsp;1, 2024. The fees payable to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on the board of directors and for service on each committee of the board of directors on which the director is a member,
effective January&nbsp;1, 2024, are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Member<BR>Annual<BR>Retainer&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Chairperson<BR>Annual<BR>Retainer ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Science and Technology Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also reimburse our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with attending our board of director and committee meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each new <FONT STYLE="white-space:nowrap">non-employee</FONT> director elected to our board of directors will be granted an initial, <FONT
STYLE="white-space:nowrap">one-time</FONT> award of a stock option to purchase 44,000 shares, which shall vest in equal quarterly installments over a three-year period from the date of vesting commencement, subject to continued service as a director
through each such vesting date. In addition, on the date of each annual meeting of stockholders of our company, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual stock option award of 22,000 shares, which
shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases
to serve as a director, unless the board of directors determines that the circumstances warrant continuation of vesting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This program is intended to
provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our directors&#146; interests with those of our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_8"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Relationships and Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than the
compensation agreements and other arrangements described under &#147;Executive compensation&#148; and &#147;Director compensation&#148; in this proxy statement and the transactions described below, since January&nbsp;1, 2022, there has not been and
there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of our total assets amounts at
December&nbsp;31, 2022 and 2023) and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had,
or will have, a direct or indirect material interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December 2022 Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022, we issued 126,815 shares of our common stock at a price of $5.52 per share and to certain investors in lieu of common stock, <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 6,213,776 shares of common stock at a price of $5.51999 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Certain existing holders of five percent or more of a class of
our capital stock participated in the transaction, as evidenced by the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Greater than Five Percent Holder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrants<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Venrock Healthcare Capital Partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,811,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,999,980.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adage Capital Partners LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">597,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,300,015.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,002.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lynx Master Fund LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">543,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,004.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May 2023 Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May
2023, we issued 8,337,500 shares of our common stock at a price of $12.00 per share in connection with an underwritten public offering. Certain existing holders of five percent or more of a class of our capital stock participated in the transaction,
as evidenced by the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Greater than Five Percent Holder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Common<BR>Stock<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adage Capital Partners LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">725,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fred Alger Management Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commodore Capital LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware
law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to our company or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which they derived an improper personal benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions
in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors of corporations, then the
personal liability of our directors will be further limited to the greatest extent permitted by the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we
adopted bylaws which provide that we will indemnify, to the fullest extent permitted by law, any person who is or was a party or is threatened to be made a party to any action, suit or proceeding by reason of the fact that he or she is or was one of
our directors or officers or is or was serving at our request as a director or officer of another corporation, partnership, joint venture, trust, or other enterprise. Our bylaws provide that we may indemnify to the fullest extent permitted by law
any person who is or was a party or is threatened to be made a party to any action, suit, or proceeding by reason of the fact that he or she is or was one of our employees or agents or is or was serving at our request as an employee or agent of
another corporation, partnership, joint venture, trust or other enterprise. Our bylaws also provide that we must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding,
subject to very limited exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into and in the future plan to enter into agreements to indemnify our directors and executive
officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding,
including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s status as a member of our board of directors to the maximum extent allowed under Delaware law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related person transaction policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors
adopted a written related person transaction policy providing that transactions with our directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related person, must be approved by our audit
committee. This policy became effective on October&nbsp;29, 2019, the date our registration statement for our initial public offering became effective. Pursuant to this policy, the audit committee has the primary responsibility for reviewing and
approving or disapproving &#147;related person transactions,&#148; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person has or will
have a direct or indirect material interest. For purposes of this policy, a related person is defined as a director, executive officer, nominee for director, or greater than 5% beneficial owner of our common stock, in each case since the beginning
of the most recently completed year, and their immediate family members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As appropriate for the circumstances, the audit committee will review and
consider: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the related person&#146;s interest in the related person transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approximate dollar amount involved in the related person transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approximate dollar amount of the related person&#146;s interest in the transaction without regard to the
amount of any profit or loss; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the transaction was undertaken in the ordinary course of our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the terms of the transaction are no less favorable to us than terms that could have been reached with an
unrelated third party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purpose of, and the potential benefits to us of, the related-party transaction; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other information regarding the related-party transaction or the related person in the context of the
proposed transaction that would be material to investors in light of the circumstances of the particular transaction. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_9"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our
common stock as of April&nbsp;4, 2024 by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, who is known by us to beneficially own <FONT
STYLE="white-space:nowrap">greater-than-5.0%</FONT> of our common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The column entitled &#147;Shares Beneficially Owned&#148; is
based on a total of 48,249,115 shares of our common stock outstanding as of April&nbsp;4, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the
rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common stock subject to options or warrants that are currently exercisable or exercisable within 60 days of April&nbsp;4, 2024
are considered outstanding and beneficially owned by the person holding the options or warrants for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other
person. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable.
Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, Pennsylvania 19104. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares beneficially owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and address of beneficial owner(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>&gt; 5% Stockholders</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,409,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Adage Capital Partners, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,864,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alger Associates, Inc.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,326,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.89</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State Street Corporation(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,594,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Venrock Healthcare Capital Partners(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,563,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,778,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gwendolyn K. Binder, Ph.D.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">463,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Chang, M.D., M.P.H.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">487,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Catherine Bollard, MBChB, M.D.(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Brun, M.D.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Henriques, MBA(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Simon, MBA(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn Tomasello, MBA(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (11&nbsp;persons)(15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,116,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise indicated, the address for each beneficial owner is c/o Cabaletta Bio, Inc., 2929 Arch Street,
Suite 600, Philadelphia, Pennsylvania 19104. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information reported is based on information in a Schedule 13G, as filed by BlackRock, Inc. with the SEC on
January&nbsp;8, 2024. In that filing, BlackRock, Inc. reports sole voting power with respect to 4,375,492 shares of common stock and sole dispositive power with respect to 4,409,005 Shares, and lists its address as 50 Hudson Yards, New York, New
York 10001. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information is based on a Schedule 13G/A filed with the SEC on February&nbsp;7, 2024. Consists of 3,266,645
shares of common stock and 597,830 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants held by Adage Capital Partners, L.P. (&#147;ACP&#148;). Adage Capital Partners GP, L.L.C.
(&#147;ACPGP&#148;) is the general partner of ACP. Adage Capital Management, L.P. (&#147;Adage LP&#148;) is the investment manager of ACP. Adage Capital Advisors, L.L.C. (&#147;ACA&#148;) is managing member of ACPGP. Robert Atchinson and Phillip
Gross are managing members of ACA and ACPGP and are general partners of ACP. Each of ACP, ACPGP, ACA, Adage LP, Robert Atchinson, and Phillip Gross have shared voting and dispositive power over all of the shares. The ability of the Adage entities to
exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is subject to a beneficial ownership limitation, which prevents the Adage entities from exercising any portion of the warrants to the extent such exercise would result in the
Adage entities exceeding a certain percentage of the total number of issued and outstanding shares of our common stock following such exercise. The address for Adage Capital Partners, L.P. is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts
02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information is based on a Schedule 13G filed with the SEC on February&nbsp;14, 2024. Consists of 3,326,401
shares beneficially owned by one or more <FONT STYLE="white-space:nowrap">open-end</FONT> investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC (&#147;FAM&#148;), a registered investment
adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC (&#147;AGH&#148;), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company. The address of the foregoing entities is 100 Pearl Street, 27th
Floor, New York, NY 10004. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information reported is based on information in a Schedule 13G, as filed by State Street Corporation
(&#147;State Street&#148;) with the SEC on January&nbsp;24, 2024. State Street is the parent holding company of SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited and State Street Global
Advisors Trust Company. Each has shared voting power over 2,518,905 shares and shared dispositive power over 2,594,470 shares. The address of these entities is State Street Financial Center, 1 Congress Street, Suite 1, Boston, MA 02114.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information is based on a Schedule 13G/A filed with the SEC on February&nbsp;14, 2024. Consists of (i)
588,410 shares held by Venrock Healthcare Capital Partners III, L.P. (&#147;VHCP III LP&#148;), (ii) 58,863 shares held by VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC (&#147;VHCP
<FONT STYLE="white-space:nowrap">Co-Investment</FONT> III&#148;) and (iii) 1,916,679 shares held by Venrock Healthcare Capital Partners EG, L.P. (&#147;VHC PEG&#148;). VHCP Management III, LLC is the general partner of VHCP III LP and the manager of
VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> III. VHCP Management EG, LLC is the general partner of VHC PEG. Messrs. Nimish Shah and Bong Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC. The address
for the individuals and entities listed above is 3340 Hillview Avenue, Palo Alto, California 94304. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 986,483 shares of common stock held by Dr.&nbsp;Nichtberger, (ii) 363,000 shares of common
stock held by the 2017 Nichtberger Family Trust, or the Trust Shares, and (iii) 1,429,186 shares of common stock underlying options exercisable within 60 days of April&nbsp;4, 2024. Dr.&nbsp;Nichtberger may be deemed to beneficially own the Trust
Shares. Dr.&nbsp;Nichtberger disclaims beneficial ownership of the Trust Shares and this shall not be deemed an admission that he is the beneficial owner of the Trust Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 20,000 shares of common stock held and (ii) 443,894 shares of common stock underlying options
exercisable within 60 days of April&nbsp;4, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 487,815 shares of common stock underlying options exercisable within 60 days of April&nbsp;4, 2024.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,000 shares of common stock held and (ii) 112,428 shares of common stock underlying options
exercisable within 60 days of April&nbsp;4, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 84,333 shares of common stock underlying options exercisable within 60 days of April&nbsp;4, 2024.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 112,428 shares of common stock underlying options exercisable within 60 days of April&nbsp;4, 2024.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 143,144 shares of common stock held and (ii) 112,428 shares of common stock underlying options
exercisable within 60 days of April&nbsp;4, 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(14) Consists of 11,000 shares of common stock underlying options exercisable within
60 days of April&nbsp;4, 2024. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See notes (7)&nbsp;through (14); also includes an aggregate of (i) 50,000 shares of common stock and (ii)
759,760 shares of common stock subject to options exercisable within 60 days of April&nbsp;4, 2024 held by Anup Marda, our Chief Financial Officer, Michael Gerard, our General Counsel and Secretary, and Arun Das, M.D., our Chief Business Officer.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_10"></A>REPORT OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee is appointed by the board of directors to assist the board of directors in fulfilling its oversight responsibilities with respect to
(1)&nbsp;the integrity of Cabaletta&#146;s financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance with legal and regulatory requirements, (2)&nbsp;the qualifications,
independence, and performance of Cabaletta&#146;s independent registered public accounting firm, (3)&nbsp;the performance of Cabaletta&#146;s internal audit function, if any, and (4)&nbsp;other matters as set forth in the charter of the audit
committee approved by the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the preparation of Cabaletta&#146;s financial statements and the financial
reporting process, including its system of internal control over financial reporting and its disclosure controls and procedures. The independent registered public accounting firm is responsible for performing an audit of Cabaletta&#146;s financial
statements in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB) and issuing a report thereon. The audit committee&#146;s responsibility is to monitor and oversee these processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with these responsibilities, the audit committee reviewed and discussed with management and the independent registered public accounting firm
the audited financial statements of Cabaletta for the fiscal year ended December&nbsp;31, 2023. The audit committee also discussed with the independent registered public accounting firm the matters required to be discussed by the applicable
requirements of the PCAOB and the SEC. In addition, the audit committee has received written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of PCAOB regarding the independent
registered public accounting firm&#146;s communications with the audit committee concerning independence and has discussed with the independent registered public accounting firm their independence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the reviews and discussions referred to above, the audit committee recommended to the board of directors that the audited financial statements of
Cabaletta be included in Cabaletta&#146;s 2023 Annual Report, that was filed with the SEC. The information contained in this report shall not be deemed to be (1) &#147;soliciting material,&#148; (2) &#147;filed&#148; with the SEC, (3)&nbsp;subject
to Regulations 14A or 14C of the Exchange Act, or (4)&nbsp;subject to the liabilities of Section&nbsp;18 of the Exchange Act. This report shall not be deemed incorporated by reference into any of our other filings under the Exchange Act or the
Securities Act, except to the extent that we specifically incorporate it by reference into such filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE AUDIT COMMITTEE OF THE BOARD OF </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DIRECTORS OF CABALETTA BIO, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Henriques, MBA,
Chairperson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott Brun, M.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Simon, MBA </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;23, 2024 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_11"></A>DELINQUENT SECTION 16(a) REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers, and persons who beneficially own more than 10% of our outstanding common
stock to file reports of their stock ownership and changes in their ownership of our common stock with the SEC. We prepare and file these reports on behalf of our directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To our knowledge, based solely on a review of the Company records and written representations that no other reports were required, we believe that for fiscal
2023, all required reports were filed on a timely basis under Section&nbsp;16(a), with the exception of certain Form 4s which were filed by the company on behalf of each of Anup Marda, David J. Chang, Gwendolyn Binder, Arun Das, Michael Gerard and
Steven Nichtberger, relating to annual stock option grant awards, which occurred on January&nbsp;18, 2023 and which Form 4s were filed on January&nbsp;27, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_12"></A>HOUSEHOLDING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some banks, brokers and other nominee record holders may be participating in the practice of &#147;householding&#148; proxy statements and annual reports.
This means that only one copy of our documents, including the Annual Report to stockholders and proxy statement, may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of either document to you upon
written or oral request to Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104, Attention: Corporate Secretary, telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-759-3100</FONT></FONT> x1100. If
you want to receive separate copies of the proxy statement or Annual Report to stockholders in the future, or if you are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other
nominee record holder, or you may contact us at the above address and phone number. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_13"></A>STOCKHOLDER PROPOSALS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A stockholder who would like to have a proposal considered for inclusion in our 2024 proxy statement must submit the proposal in accordance with the
procedures outlined in Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> of the Exchange Act so that it is received by us no later than December&nbsp;24, 2024. However, if the date of the 2025 Annual Meeting of Stockholders is changed by more than
30 days from the date of the previous year&#146;s meeting, then the deadline is a reasonable time before we begin to print and send our proxy statement for the 2024 Annual Meeting of Stockholders. SEC rules set standards for eligibility and specify
the types of stockholder proposals that may be excluded from a proxy statement. Stockholder proposals must be delivered by mail to and should be addressed to Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104, Attention:
Corporate Secretary. We also encourage you to submit any such proposals via email to proxyproposal@cabalettabio.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a stockholder wishes to propose a
nomination of persons for election to our board of directors or present a proposal at an annual meeting but does not wish to have the proposal considered for inclusion in our proxy statement and proxy card, our bylaws establish an advance notice
procedure for such nominations and proposals. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a
stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate secretary of the stockholder&#146;s intention to bring such business before the
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90 days nor more
than 120 days prior to the first anniversary of the preceding year&#146;s annual meeting. However, in the event that the date of the annual meeting is advanced by more than 30 days, or delayed by more than 60 days, from the first anniversary of the
preceding year&#146;s annual meeting, a stockholder&#146;s notice must be so received no earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of (A)&nbsp;the 90th day prior to such annual
meeting and (B)&nbsp;the tenth day following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought
before the 2025 Annual Meeting of Stockholders, the required notice must be received by our corporate secretary at our principal executive offices no earlier than February&nbsp;3, 2025 and no later than March&nbsp;5, 2025. Stockholder proposals and
the required notice should be addressed to Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104, Attention: Corporate Secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, to comply with the SEC&#146;s new universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice by the same deadline noted herein to submit a notice of
nomination for the 2024 Annual Meeting of Stockholders. Such notice must comply with the additional requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(b).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc448465_14"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned in this proxy statement
are properly brought before the meeting, the individuals named in the enclosed proxy intend to use their discretionary voting authority under the proxy to vote the proxy in accordance with their best judgment on those matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">&#8194;


<IMG SRC="g448465dsp2a.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">P.O. BOX 8016, CARY, NC 27512-9903</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g448465dsp2b.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#88241b"><B>Scan QR for</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#88241b"><B>digital voting</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#88241b"><B>Cabaletta Bio, Inc.</B></FONT></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g448465dsp2c.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#5e5e5e">For Stockholders of record as of April&nbsp;4, 2024</FONT></P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#88241b">Monday, June&nbsp;3, 2024 at 9:00 AM, Eastern
Time</FONT></P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#88241b">Annual Meeting to be held live
via the internet - please visit</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#88241b">www.proxydocs.com/CABA for more details</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #88241b" align="left">&nbsp;</P> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>YOUR VOTE IS IMPORTANT!</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PLEASE VOTE BY: 9:00
AM, Eastern Time, June&nbsp;3, 2024.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g448465dsp2d.jpg" ALT="LOGO">
</P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g448465dsp2e.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g448465dsp2f.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g448465dsp2g.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#88241b"><B>Internet:</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><FONT COLOR="#595959"><B>www.proxypush.com/CABA</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL"><B>&#149;&#8194;&#8202;</B>Cast your vote online<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL"><B>&#149;&#8194;&#8202;Have your Proxy Card ready</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL"><B>&#149;&#8194;&#8202;</B>Follow the simple instructions to record your vote<B></B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#88241b"><B>Phone:</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><FONT COLOR="#595959"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-430-8263</FONT></FONT></FONT></B></FONT></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL"><B>&#149;&#8194;&#8202;</B>Use any touch-tone telephone<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL"><B>&#149;&#8194;&#8202;Have your Proxy Card ready</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL"><B>&#149;&#8194;&#8202;</B>Follow the simple recorded instructions<B></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><FONT COLOR="#88241b"><B>Mail:</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL"><B>&#149;&#8194;&#8202;</B>Mark, sign and date your Proxy Card<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL"><B>&#149;&#8194;&#8202;</B>Fold and return your Proxy Card in the postage-paid envelope provided<B></B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><FONT COLOR="#88241b"><B>Virtual:</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:ARIAL">You must pre-register to attend the meeting online at www.proxydocs.com/CABA</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#88241b"><B>This proxy is being solicited on behalf of the Board of Directors </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The undersigned hereby appoints Steven Nichtberger, M.D. and Anup Marda, the true and lawful attorneys of the undersigned, with full power of substitution and revocation,
and authorizes them to vote all the shares of common stock of Cabaletta Bio, Inc. which the undersigned is entitled to vote at said meeting and any adjournment thereof upon the matters specified and upon such other matters as may be properly brought
before the meeting or any adjournment thereof, conferring authority upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED FOR THE ELECTION OF THE DIRECTORS IN ITEM 1 AND FOR THE
PROPOSAL IN ITEM 2. THE PROXIES WILL VOTE IN THEIR DISCRETION ON ANY OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING AND ANY ADJOURNMENT THEREOF. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">You are
encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors&#146; recommendation. The named proxies cannot vote your shares unless
you sign (on the reverse side) and return this card. </P> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right">Copyright &copy; 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g448465dsp3a.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#88241b"><B>Cabaletta Bio, Inc. Annual Meeting of
Stockholders</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="middle"><FONT STYLE="font-size:8pt"><B>Please&nbsp;make&nbsp;your&nbsp;marks&nbsp;like&nbsp;this:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">


<IMG SRC="g448465dsp2.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The Board of Directors Recommends a Vote <B>FOR</B> the director nominees listed in Proposal 1 and <B>FOR</B> Proposal 2.
</P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom" BGCOLOR="#cccccc"></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><B>PROPOSAL</B></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #595959" BGCOLOR="#cccccc" ALIGN="center"><B>YOUR VOTE</B> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL" ALIGN="center"><B>BOARD OF DIRECTORS RECOMMENDS</B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top" ROWSPAN="2"><FONT STYLE="font-size:8pt">1.</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">To elect two class II directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until their successor
has been duly elected and qualified, or until their earlier death, resignation or removal.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">1.01 Catherine Bollard, MBChB, M.D.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL">1.02 Richard Henriques, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>FOR</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>WITHHOLD</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #595959"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g448465dsp3c.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #595959"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>FOR</B></P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>FOR</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #595959">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #595959">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>FOR</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>AGAINST</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #595959"><B>ABSTAIN</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" NOWRAP>2.&#8194;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">To ratify the appointment of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2024.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #595959"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>FOR</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #595959">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NOTE: To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #595959"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; margin-right:5%; font-size:8pt; font-family:ARIAL"><B>You must <FONT STYLE="white-space:nowrap">pre-register</FONT> to attend the meeting online at www.proxydocs.com/CABA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; margin-right:5%; font-size:8pt; font-family:ARIAL">Authorized Signatures - Must be completed for your instructions to be executed. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; margin-right:5%; font-size:8pt; font-family:ARIAL">Please sign exactly as your name(s) appears on your stock certificate. If held in joint tenancy, all persons should sign. Trustees,
administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the proxy. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="8%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Signature (Title and name of Corporation if applicable)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Date&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8199;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.80em; font-size:8pt; font-family:ARIAL">Signature (if held jointly)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Date&#8195;&#8195;&#8195;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g448465dsp2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MK6+3M&U;X9^,=*TC3EOA%<1Z?IUO<7=C96T$C1H&E"(=TBI1L&Q^V] !0 4
&% !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g448465dsp2a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp2a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MB"YDAE_Y;8YIVHKKL1M\CVS]G/\ :DTWXY:GXM\"^(/!.N_"GXO_  ^^S_\
M"8?#?Q/)%)>P6,KB&+6=(O8H8QJ.CF651GR5*_:[4_-;W=O/<DX6]"]O*Q?\
M0?M-Z5X>_:?\$_LRR>!_%MUJ?C'PQ=^)8?&<$,$?A^T$-GK>HK$+5C]HU"R5
M/#]W'=ZE /)L[J_L;:;YKL87+97[!M\CZFJ0#'&.G;Z?A0!SGBK75\,^&==\
M0O:RW:Z+I%]J?V2(E99OL=K+<",R '[.C>5@R8.P9;'RXH0;?(\$^&GQC\4:
M_P",(_#/B;2M.A2]U#6-)M[K3%EMU&IZ-976ISWFG+/<N=8\)36MI/!%J0CC
M)NE':XV6M-67H&WR/IZI _*_XNZ"?VG/VZO"_P %/$R->?"7X ^"[/XD^*?#
M<CK_ &?XE\5:RMJVG1:I;.2+R!8-3T%?*(.VV34XL@7YKRJR^L8V-)[4ES_<
MTEY_:_$^[RVJLDX3Q>9T9<N+S>JJ#TT]FHU&[73UBZ:MT[IIJWZC6L<-NB6]
MO''!#;Q1Q0P1*B)#$@V1QHB !(E50BJ  NPJ.E>M;E279'PMW)1G+XI*[_KN
M%Y;P75K/:W,$-S;7,4MO<6UQ$L]O<02QO'+#/ X*S0NC%6C8$,I*GK2<8M.,
MMI*P*4J?O0TG'X+?S+5?D?,N@> /@E^QKX%^)_C/0QJGA+P"T]UXV\2Z0VKW
M^J:1IUZ-\ C\+Z->W#)IUQ=O-96,5I:^6)S#I\*G**&Y4J."ISY=+7?](]FI
MB<QXDQ.!PM6*K8Q15&DMM-]>G2]TEUT/ES0M'_X* ?M":;:_$O3_ (M>$/V=
M/!OB1/[9\$^!;3PG9^)O$*>&KT>?H-UXFN[VSE87UUITEO<.@NP!YI)LK5RU
MO'RQ688B$:L*RH1=W%=UT^ZWXGT5:MPEDE66#EE?]M5Z2C#$56W;VD-)02;L
MO9MR6G?5NQI>&_VBOCK^SW\3?"7PC_:[A\/^)/#7Q OHM(\ ?'OPA9C2-*EU
MN22*W31O&&G"&"VMI#)/:(\ZVUFL!E61A=6_G7%A<,1B,-6ITL1453VFD6K*
MUK)_^E=M^IEB,CRC-\%B<RX=<L+BL+:57"O7V<9N=DM6[OV;MJXVBK)=)O\
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3 4 % !0 4 % !0 4 % !0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g448465dsp2b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp2b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M=+VN+=>I2G&DZEOJ]*/LJ5)QJ.*G5J*=^6G*@TK5;K[6KH/D H * "@ H *
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MZ63Y?'-,SP>6RQ,<(\945*%64>:,:DTU24ES1LIU.6#E>T>;F=TK'Y]>!_\
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ME73VNMO7V=E]SL?HE+PD_=KVV><M6VJAA>:$7KHG+$1<EMJXQZJW4]M^#_\
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MVSUNN"KXMSLU0R&,7TE/&-V_[<CA5?M_$C;?6UGWVE?\$LO \ 3^W/BOXKU
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MC:30]&M8FN%'#$#5(N>.>M<6(XDJM..%P\:>FDZC<WYVA'E2MT;E)/K'2S>
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M?\3ZZGXA\5TX1I_VA&7*DE*6'P[EHK*[]FKONWJWJVSUSX8_LU_!'X/W O\
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M59OC<)A<9A9.MEV 4I5\/!>_";T^LNS_ 'D(P]QJUZ*YIZPG4<.CKZX_"0H
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M^ _A;4[C7->L?^$QN=(OI/"GA.%S=:OJFI&VF73I)K.W5WL=*-VJB2]N1%"
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M]%ATS7?'#Q2%7U+5[R%-0T71I@N/]"LK&6TOV4EA)/>VY(5K-2WRO$&/<>7
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M1_$ZWBSCIXIU,#EN'_LUR_=JLZOUB=*_NSE.,XPI2J1][D]G4]G?E<IM-O\
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MSSC_ #3/<KQ.58K"86C0Q+I.4Z4:RFO95J=>/*YUIQUE32=XOW6[6=FO+/\
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MW?EC&,7*K-)N*<(JSJ*4?R9\+_$']LO]I_Q1<Z/X3\=>.]4NX(S>:A%H.O\
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M *CM]7N<&_QL[_[%K_\ 5AEYQ^*O_),4?^QAA?\ W*?K_P#MI?\ )L'Q;_[
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MN7BC_P!3+Q#7ZU6_W?*?^Q7EG_J#0/Y\XR_Y*_B3_L*I_P#J%A#YK_X*E_\
M(A_"O_L;M9_],R5^=\5?\C;*?^P3'_\ I[ 'Z!X2?'GW^'!_GB3RO_@EC_R.
M7Q9_[%GP[_Z=;VOI.%O^1/FO_89@O_3&.,_%W_>>&_\ KUF?_I67&E_P5-\/
MZHNL_"?Q2(97T5M,\0: ]PJL8;;4TNK/48H97SM26XM7F:,8!86$IYV''RO$
M-*5+/'5EI#$X*A&GH[-X>MB?:J^UXK$46U_?7F>MX3XBE+*\TPBDE7H8J-:4
M;^\Z=6E&$9);M1E1DI/HY1O;F5_(_P!A;]I[X=? 5?'&A?$.#4K*S\47&D:C
M9>(-,TYM3\B73(;NWDT_4+>W/VD0LMR)(7ACF ;S@RKN#'W,ESK!87*GE^)E
M*C4I8JMB(RY7*$XUZ6&I.'NIN,Z;PZDKKEE&<O>BXI3?'_!^;9[CL#F.5\E?
MV&'>&J4)U(TW"U256-6DYM4VI\SA63E&7[NA937-R=U^U[^V-HOQT\(R_"KX
M/:%XBU31GE3Q#XLU^[TJ:&2;2_#BG5C%8:9#YMQ!IMM+ EY=W]VML(ET_&PQ
M,TH\C.<=+-)4UAZ<XX++I.O.=M92:^KPG.UU3HQ==Q3DTYU:E->YRI5+X)X/
MJ<-XG^T\XQ%&CC,0EA,+0C46DZTK-<[:4ZU10Y*=*GSWC*6\K*/B'_!/G_DY
M_P '_P#8&\7?^H[?5[/!O\;._P#L6O\ ]6&7F_BK_P DQ1_[&&%_]RG[.?M7
M>'M0\3_LZ?%O1]+ADN+YO"5U?P6\,;2S7 T6>WUF6"&)/FDE>&PD554$EF
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M?PK_ .QNUG_TS)7Q?%7_ "-LI_[!,?\ ^GL ?<>$GQY]_AP?YXD\Y_X)7?\
M(?\ C%_V!_"'_I;KM?3\,?\ (BQW_8?0_P#4>L8^+O\ O?#?_7G,_P#TO+C]
ME*]4_(CXU_:7_:VM_P!FSQ;X'TK5O!TWB;0?%>E:M>WESIVI)8ZOIDNFW=I
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M3O&46XSC*+:?F95FV/R7%PQN75W0KP3B]$XS@[7A4@[QE!V5TUHTI1:E%-?
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M(I3IWJ24JB<80X*_^*FK^$/&GQ'7PS8M-K'Q"^+/@K1].GN/#.N^,H]&ME^
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M^IY;+!U*LL/A_K%.K4Q^9UZOU;%.$L11A/#XNC"4J52D^93LDTIR]$UOX2^
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MT;Q=!9?#"36/B1X8QJ5U/=>#&O;VS%U=P1ZNL'VJ9[B2-1+G6G4E]5_M&M'
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MG_SYQ/\ X35__E8?ZN8K_H895_X=LO\ _F@/^&C/#_\ T3/]H/\ \,+\3O\
MYGJ/KU/_ )\XG_PFK_\ RL/]7,5_T,,J_P##ME__ ,T!_P -&>'_ /HF?[0?
M_AA?B=_\SU'UZG_SYQ/_ (35_P#Y6'^KF*_Z&&5?^';+_P#YH#_AHSP__P!$
MS_:#_P##"_$[_P"9ZCZ]3_Y\XG_PFK__ "L/]7,5_P!##*O_  [9?_\ - ?\
M-&>'_P#HF?[0?_AA?B=_\SU'UZG_ ,^<3_X35_\ Y6'^KF*_Z&&5?^';+_\
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M*/P-H * "@ H * "@#^A?PY_R<W\5?\ LD'P>_\ 4G^+-<5/_D88G_KQA_\
MTO$'OXC_ ))C*?\ L8YE_P"H^6GT#7:> <A=^ _"M[IFJ:1/IC_8M8UL^)+T
M0ZCJEM=C7C<V]XFK6.H6U['=Z5?17=I;RQ264UN87B!BV<YF,%"&&A3<J:P;
MJNBXR<94W6J5ZM6TD^9JI+$XA3C)RC*G5G1DG1?(._OXB<DI/%1A&LI)2C.-
M*C1P]-.#3BN2EAZ*BTDXSIQJIJJN<YNY^#/P_NK:"VET_65,*:U%<7UOXO\
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MT#7:> % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M^!MM_P#':+KNOO#V=3_GW+_P%_Y!_:^D_P#04T[_ ,#;;_X[1==U]X>SJ?\
M/N7_ ("_\@_M?2?^@IIW_@;;?_':+KNOO#V=3_GW+_P%_P"0?VOI/_04T[_P
M-MO_ ([1==U]X>SJ?\^Y?^ O_(/[7TG_ *"FG?\ @;;?_':+KNOO#V=3_GW+
M_P !?^0?VOI/_04T[_P-MO\ X[1==U]X>SJ?\^Y?^ O_ "#^U])_Z"FG?^!M
MM_\ ':+KNOO#V=3_ )]R_P# 7_D']KZ3_P!!33O_  -MO_CM%UW7WA[.I_S[
ME_X"_P#(/[7TG_H*:=_X&VW_ ,=HNNZ^\/9U/^?<O_ 7_D']KZ3_ -!33O\
MP-MO_CM%UW7WA[.I_P ^Y?\ @+_R#^U])_Z"FG?^!MM_\=HNNZ^\/9U/^?<O
M_ 7_ )!_:^D_]!33O_ VV_\ CM%UW7WA[.I_S[E_X"_\@_M?2?\ H*:=_P"!
MMM_\=HNNZ^\/9U/^?<O_  %_Y!_:^D_]!33O_ VV_P#CM%UW7WA[.I_S[E_X
M"_\ (/[7TG_H*:=_X&VW_P =HNNZ^\/9U/\ GW+_ ,!?^0?VOI/_ $%-._\
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M .L&-4.;DYOKE;EY[TX\E_:6YKUJ2Y=[U::M><;U!\+/V2H;V]T_4_AA\'M
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M#3_$,NA>%#HMW=7\YM[9(-3C@:W=#(DA:42>7&D,LDC)'$[*_P"S<$J]#"O
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M5J4I2BE)TYRC>SL%5*5!4FOW=6M#G6W,J?[^";5FXQK4:=3EORN4%=-73[/
M!S@ X SC!P,D#/H"3^=+;R#MY;?A?\E]R *H!4* #G*@  [B2V1[DDGZFCRZ
M=@6FVEM@VKC;@8&,+@8&T@KQ[$#'TH"UE;96M;RVMZ6TL(40Y!12&(+ J#DK
MC:2".2-HQZ8'I1MY6U7K_2#_ "M\M;KTU>FVK[AM7+?*N6 #<#+  @!O4 $]
M?6BVC71[KY)/3T27HD&S3V<=GVLVUZ6;;]6PVJ %VJ%7;M7  7805P.@VD#&
M.F!1UOU[_@_S8))*R5DMD*0""I (((*D9!!X((/;% )VM;1K84    8 X '
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@:O\ R;-\2_\ N3?_ %8'A6@#\#: "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g448465dsp2c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp2c.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M?_S?T?ZR8[_GU0_\!J?_ "T/^(5</?\ 09F/_@[#?_,@?\//OCY_T*/P@_\
M!!XS_P#F_H_UDQW_ #ZH?^ U/_EH?\0JX>_Z#,Q_\'8;_P"9 _X>??'S_H4?
MA!_X(/&?_P W]'^LF._Y]4/_  &I_P#+0_XA5P]_T&9C_P"#L-_\R!_P\^^/
MG_0H_"#_ ,$'C/\ ^;^C_63'?\^J'_@-3_Y:'_$*N'O^@S,?_!V&_P#F0/\
MAY]\?/\ H4?A!_X(/&?_ ,W]'^LF._Y]4/\ P&I_\M#_ (A5P]_T&9C_ .#L
M-_\ ,@?\//OCY_T*/P@_\$'C/_YOZ/\ 63'?\^J'_@-3_P"6A_Q"KA[_ *#,
MQ_\ !V&_^9 _X>??'S_H4?A!_P""#QG_ /-_1_K)CO\ GU0_\!J?_+0_XA5P
M]_T&9C_X.PW_ ,R!_P //OCY_P!"C\(/_!!XS_\ F_H_UDQW_/JA_P" U/\
MY:'_ !"KA[_H,S'_ ,'8;_YD#_AY]\?/^A1^$'_@@\9__-_1_K)CO^?5#_P&
MI_\ +0_XA5P]_P!!F8_^#L-_\R!_P\^^/G_0H_"#_P $'C/_ .;^C_63'?\
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M  \^^/G_ $*/P@_\$'C/_P";^C_63'?\^J'_ (#4_P#EH?\ $*N'O^@S,?\
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M #?T?ZR8[_GU0_\  :G_ ,M#_B%7#W_09F/_ (.PW_S('_#S[X^?]"C\(/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MF,<KQ%#%XC%5,-3Q-)8:E"JJT:M6K1A2I_O8RE5;HSE9Q5/DL_:7?*6/B/\
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M=W=MMMRD]W*4I/5LY&F=(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!^OG_!*;_FO/_=+O_>BU]5PQ_P QW_<'_P!RGXSXN?\
M-/\ _<]_[IG>_MJ_LW_%;XO_ !3T#Q+X%\#V_B72+#X?Z5H5Q?2ZSX3TYH=1
MM?$7BJ_EM!!KNL6EPRK;:G9R;TC:,^>0&+*X7Z2IAL-6DI5</3JRBK)SIQD[
M*[2O)-VNV[>;/RK"9MFN INC@<SQ>"HRDYN%#$5J,'-I1<G&G.,7)QC%.35[
M12O9(^0/^&&?VBO^B36?_A4?#G_YIZS^H8'_ * J'_@FG_\ (G3_ *Q\0_\
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M ,M#_AAG]HK_ *)-9_\ A4?#G_YIZ/J&!_Z J'_@FG_\B'^L?$/_ $/LQ_\
M"W$__+0_X89_:*_Z)-9_^%1\.?\ YIZ/J&!_Z J'_@FG_P#(A_K'Q#_T/LQ_
M\+<3_P#+0_X89_:*_P"B36?_ (5'PY_^:>CZA@?^@*A_X)I__(A_K'Q#_P!#
M[,?_  MQ/_RT/^&&?VBO^B36?_A4?#G_ .:>CZA@?^@*A_X)I_\ R(?ZQ\0_
M]#[,?_"W$_\ RT/^&&?VBO\ HDUG_P"%1\.?_FGH^H8'_H"H?^":?_R(?ZQ\
M0_\ 0^S'_P +<3_\M#_AAG]HK_HDUG_X5'PY_P#FGH^H8'_H"H?^":?_ ,B'
M^L?$/_0^S'_PMQ/_ ,M#_AAG]HK_ *)-9_\ A4?#G_YIZ/J&!_Z J'_@FG_\
MB'^L?$/_ $/LQ_\ "W$__+0_X89_:*_Z)-9_^%1\.?\ YIZ/J&!_Z J'_@FG
M_P#(A_K'Q#_T/LQ_\+<3_P#+0_X89_:*_P"B36?_ (5'PY_^:>CZA@?^@*A_
MX)I__(A_K'Q#_P!#[,?_  MQ/_RT/^&&?VBO^B36?_A4?#G_ .:>CZA@?^@*
MA_X)I_\ R(?ZQ\0_]#[,?_"W$_\ RT/^&&?VBO\ HDUG_P"%1\.?_FGH^H8'
M_H"H?^":?_R(?ZQ\0_\ 0^S'_P +<3_\M#_AAG]HK_HDUG_X5'PY_P#FGH^H
M8'_H"H?^":?_ ,B'^L?$/_0^S'_PMQ/_ ,M#_AAG]HK_ *)-9_\ A4?#G_YI
MZ/J&!_Z J'_@FG_\B'^L?$/_ $/LQ_\ "W$__+0_X89_:*_Z)-9_^%1\.?\
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M/^&&?VBO^B36?_A4?#G_ .:>CZA@?^@*A_X)I_\ R(?ZQ\0_]#[,?_"W$_\
MRT/^&&?VBO\ HDUG_P"%1\.?_FGH^H8'_H"H?^":?_R(?ZQ\0_\ 0^S'_P +
M<3_\M#_AAG]HK_HDUG_X5'PY_P#FGH^H8'_H"H?^":?_ ,B'^L?$/_0^S'_P
MMQ/_ ,M#_AAG]HK_ *)-9_\ A4?#G_YIZ/J&!_Z J'_@FG_\B'^L?$/_ $/L
MQ_\ "W$__+0_X89_:*_Z)-9_^%1\.?\ YIZ/J&!_Z J'_@FG_P#(A_K'Q#_T
M/LQ_\+<3_P#+0_X89_:*_P"B36?_ (5'PY_^:>CZA@?^@*A_X)I__(A_K'Q#
M_P!#[,?_  MQ/_RT/^&&?VBO^B36?_A4?#G_ .:>CZA@?^@*A_X)I_\ R(?Z
MQ\0_]#[,?_"W$_\ RT/^&&?VBO\ HDUG_P"%1\.?_FGH^H8'_H"H?^":?_R(
M?ZQ\0_\ 0^S'_P +<3_\M#_AAG]HK_HDUG_X5'PY_P#FGH^H8'_H"H?^":?_
M ,B'^L?$/_0^S'_PMQ/_ ,M#_AAG]HK_ *)-9_\ A4?#G_YIZ/J&!_Z J'_@
MFG_\B'^L?$/_ $/LQ_\ "W$__+3[_P#V&/@9\1?@O_PM'_A/O"4/A;_A)/\
MA"?[)\G5/#FI?;O[&_X2[[?N_P"$?U.\\GR?[5L\>?Y>[[0?+W;7V[4L/0P_
M-[&C3H\UK\D(PO:]K\J5[7=K[79QXO,LQQ_L_K^/Q&-]CS>S^L5ZM;DYN7FY
M/:2ER\W+'FM:_+&^R/O^M3B"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
5 "@ H * "@ H * "@ H * "@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g448465dsp2d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp2d.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "4 *P,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /U/^(GCWXKZW\0O&'@/X8WEIX8TOX8>"]%\8>,->C\)IX\\
M6>(-0\2KK4N@^$O"'A>YU?3++S9;30KYWN+F[+O,\,4:QJC-/YE>OBI5ZM##
M-4HX:G&I.7)[2<G/FY84X.45JHO5O>RTZ_79;E^48?+<%F&:0EBJN:8FKAL-
M2>(^J8>C"A[)5<1B*\:=6=HRJQ2C&%E%.3;;2CGVVG?M$W&M1:-_PN#7K<2:
MU>:-_:US^SSX9CT6(6GAV'Q -7EO!XZ9ET6=I?[+AN/*+/J,4EN8U5?-,J./
MYU#ZU)>\X\SPL.72'-S7]I\+^%.WQZ6ZFDJG#<*#K?V-2ERTHU/9QSBNZOO5
MG1]FH_54O:QM[64;V5%J=V_=.T_X5Y^T/_T<=I/_ (9+P_\ _-76WL,?_P!#
M"/\ X3Q_^3.'^TN&_P#HF:G_ (<ZW_S.'_"O/VA_^CCM)_\ #)>'_P#YJZ/8
M8_\ Z&$?_">/_P F']I<-_\ 1,U/_#G6_P#F<XOQQJ_QZ^"&F6?Q!U_XB^&_
MBGX-T_6M TSQ?X:?X?6O@O6+?2/$&MV&@C6O#^KZ9KMXDVH65YJ-K*UI=6_E
M2PB?]XCA67&M+'8**KSKPQ-&,HQJ0]DJ<E&4E'FC)2>L6T[-6:OJCNP%'A[/
M*L\MP^6ULHQLZ56>'K+%RQ--U*-*=7V5:G.E!J$XPDE.$N:,N71JZ/KVO5/C
M3XQA^%GP^^)?[2WQY_X3KPOI_B3^Q/"'P/\ [*^W-=+]B_M&T^('V[ROLUQ%
M_KOL%GNW;O\ 4+C'.?(6&H8C,<;[:DI\E/#\M[Z756^S6]E]Q]N\VS'*^%^'
M_P"S\7/"^WQ&:>TY.7WN26#Y+\R?P\\K6[LM_$CX1?LQ?#31K74-2^$^GZMJ
MNL7\.B^%O"^BIJ=UKOB?7KD'[+I6EVW]H@;C@O+/(5BAC4N[9VJ_3_9N!_Z!
MH_C_ )GE?ZV<1?\ 0UK?=#_Y ^0-6\+>(&@^*.O:-^S?\"+/0/A.UL/$VFWN
MI>.-=UB&<V4&JZOI-IJNF^(;&QU'4=%TJX2?4'CMXX4P5MFN7^2C^S<#_P!
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$>"?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g448465dsp2e.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp2e.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M &W]I.^,P_MW#EQ:TI^_'E4K^]O>T>QZE_PS*O\ T<!^TY_X=F3_ .4E=/\
M9W_4=B__  =_]J>3_K3_ -4[D?\ X;U_\M,[3OV?=(U;[=_97[27[1VH_P!E
MZC=:1J/V'XQI=?8-5L2@O--O/(T=OLU] 9(_,@DVNF]=RC(H_L[_ *CL7_X.
M_P#M0_UI_P"J=R/_ ,-Z_P#EI%^R%IG]B>%/BWHW]H:IJW]D?M%_&/3/[5UN
M[-_K.I_8-?BM/[0U>^*)]MU2X\KSKB?8GF2R2/M&[ C*H^SI8J',Y<F*KQYI
M.\G:5KR?5NUV^K-N,JOM\7D];V<*'MLFRV?LZ4>2E3YZ+ER4X7?+"-^6$;OE
MBDKNQQ&H^.;WX9_$#]MSQUIME:ZA?^&]-^!]]:V5\TR6D\S>"Y+95N#;LLGE
MKY^XA&4G;C<,Y%X;_D89GY?5_P#TTS'-O^29X2_[JG_J7$[[XQ_$*WU9=3\*
M:6NJ6&I> ?C5\ M*U>\$B06]^GBG7?#&OQ)9O;SF5X!97JPS),D8+!@ ZG->
MB?+'GG@WQ3KOAWQ/<V&CWQM+3Q1^VK\1]"UZ$0V\HO\ 2F\'75\;1VFB=H5^
MV6EK-NB,;[K=1NVY5@#T_P#9=_Y!WQR_[.?^.7_J4UYN6_#C?^PS$_\ I9]5
MQ7_%R'_L1Y7_ .F#@O\ A T^)OQ-_;3\!2:FVBIXFL?@=8'5$M!?M9;?!4MR
M)19M<VXN.8 NSSH^&^]Q3PW_ ",,S_[E_P#TTQ9M_P DSPE_W5/_ %+B>P:[
M\#(-;UWQGK?_  DLMJ_C#Q_\*/'4EO\ V4DRV#?"^+0H%TQ)/[00W"ZE'HIS
M<%8_L[7.?*G$>V3T=CY;8CL_@-;6FL66K?\ "33N;3XX^(_C28/[*C423:_H
M-YHG_".B3[>?+B@-S'/]MVL9/):/R$\P/&;!L8'[+O\ R#OCE_V<_P#'+_U*
M:\W+?AQO_89B?_2SZKBO^+D/_8CRO_TP?/'Q'\,?L]Z=^T;\6=4_:9T33[?3
M?%ND?#K4?AMXA\1PZ_;Z%>0:/X=DT3Q3IMIJVE2);C58;^UL7DM)V\SRFBD0
M;6-<&(IX".88J68P48U8TG1E/F46HQY9I2CIS)I73UM9GTF68KB.IPUD]'A:
MO.57!U,9#&T:+I.K%U*RJT)RIU$Y>S<)22G'3FO%ZI'D?Q=L/V*8_#^D'X+I
M\!9_$A\5:,NL)XPUCQDFG+X3/VH:O);&VU!&^W+-]@.,EO(^U>4K3B('EQ4<
MG5.'U/ZLZG/'F]I*I;DUYK6>^WRO;6Q[.35..?K%;^W'FT<*J%3V?U>GAN?Z
MPN7V:ES0:Y;<_ES\G,U'F/4VT[_@F2BLQD^&1"J6(75/%KL0HR=J)=EG; X5
M02>@!-=/+PXO^?.G]Z?^9Y*J>*6BMCE_VYAU^+CH?0/['?AV#P_\,/$4VEZ%
M?>&_"OB7XJ_$3Q1X#TG4K.\TZ]M_ >I:R(O"C2V.H?Z3;(^E6<+QK.6=HFB?
M<P<,>_*::I8:IRP=*E4K59THM--4W*T-'JO=6E^ECYSC3$RQ&:X:-6O'$XO"
H8#!T,54A*,XO%TZ5\1:</=E:I)J7+HI75E:Q]75Z9\B% !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g448465dsp2f.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp2f.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M*M[@11([JLD\TTD2I'%&NXY+9)  '/ !;N=$\,V4$MS<Z;80P0+O=VA7  X
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#C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g448465dsp2g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp2g.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MI>.-=UB&<V4&JZOI-IJNF^(;&QU'4=%TJX2?4'CMXX4P5MFN7^2C^S<#_P!
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$>"?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g448465dsp3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp3a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MB"YDAE_Y;8YIVHKKL1M\CVS]G/\ :DTWXY:GXM\"^(/!.N_"GXO_  ^^S_\
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MUK)_^E=M^IEB,CRC-\%B<RX=<L+BL+:57"O7V<9N=DM6[OV;MJXVBK)=)O\
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3 4 % !0 4 % !0 4 % !0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g448465dsp3c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465dsp3c.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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B?I#0 4 % "!5484!1DM@  98EF.!W+$DGU)- "T % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g448465g01a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g448465g01a02.jpg
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M 0<("0 *$1(3%!46%R$B(S$W.7>W.G:UMA@:)"8T5EAU>)>8M-+6_\0 ' $
M 04! 0$             !@ #!0<(! $"_\0 51$  @("  0$ @4%!Q$##0
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MLR1D'B#"5M#LLL-J?>7E#+3;2<X0VE./<"S/B*3.S.Q23;,2S'4T@&R22>P
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M\+_4O:Q <V-6>;^OMF605O,@K6S&Q<6(L]Q/[7,8Q#[9TQ!ZPRX[[994VN>
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MMOY^]AF[+5QWZ=M=DQU I[^0[1R,FH6"^_/$60^)BQ9E;^PNE:RJLM@<Y=:
MDHZ4V79! \R<0/#2395?"#9\UDLG8>K@XB(HSI[3*NR-ZZ]R#RXHSW*@AI7
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MUQ85?SK4TSG98\;J_P"4B=7_ /VXVS_Z063_ ._DC_53B/\ TDW_ +A^ ?\
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M,H=<5G*$OUW",Q.^Z^VOF/F1PS,I8#6NQ]_PX&@# =^T8 '& \^M3#@QX@X
M8Z$CYPP((R@<=E*U\:5.9PTRVA"5+6I><)QE2LJ]\^/?UN?_ #9_I_M<-[D'
MZ7]/X.+)H?2ISIYR6*J7KL;YVD7[541(?B(-)H%CN-IDROAG+)PT,#:JG2:%
MK@PYI2F7[!$U:SF.C)PPL+/R;='^3,D>Q%'H_,Z_F))_ D<?0C9]%VV/E^'\
M&O?AJ/4.H]=:&UI3=/ZEJL;2M=4"%'@:M6XM+F!@ 6%+=<<=??6Z6?(R!CQ,
ME+RQ[Y,E,2IALI)E%'ED$.<I)8DD[)[DGA\  :'8#@&_"OA9M+57<SS6Y1V&
M?H!FO]JU#:T97H>&E;$1<0W[%LO4L\$N:CSJK'0H[+0=;.;*4#89%:"71$,M
MOM.//,/NX,$:=]@@GY>C??OW^7#2 ^:Y]B#^T<'2VCK"@[IUY;]4[2J\9=-?
M7R#,KMKK$PTIP&5BS4XPXWE32VB1"AW4M&1TB$^-(Q<B.+)1I0IX@Y#3 )!!
M!T0=@_?PZ0"-'N#PH9R&Z\^:_3O(V_>_ 7F*B T)8);+\AKB^H?/F67\MN+#
MCINJFTZW:SOCP(+3@8MV)!J5C'&6D0<1E7U37>M94E 61"6 _.'WG\01[=NX
M]>.=E:,[5NW<Z/R&NWR/%":=WSV_]O$@=Q\:Y<4'65)DQ21;NW#0>->/2\ E
MM:)EAT_7M"<L\TT4!@AEZM/6B#@)IMU0,IEL5Y:T>E88AU=#,1Z;T>_X;U^O
M1(]N%N1^W4 "3Z=O0G[M^WSX:;ZZNMC1O7)JXRG:VR3;=@6W[ K:.W9X(<2Q
MW:0 0[@,(4)APEFMU&(<)+5!5<4LS F27RI.2F98@F3?YI)&D;9[ >@^7_,G
3W/#R($&AW)]3\^"(>-\??'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
